<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S022352341630890X</prism:url><dc:identifier>doi:10.1016/j.ejmech.2016.10.028</dc:identifier><eid>1-s2.0-S022352341630890X</eid><prism:doi>10.1016/j.ejmech.2016.10.028</prism:doi><pii>S0223-5234(16)30890-X</pii><dc:title>Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>124</prism:volume><prism:startingPage>1006</prism:startingpage><prism:endingPage>1018</prism:endingpage><prism:pageRange>1006-1018</prism:pagerange><dc:format>text/xml</dc:format><prism:coverDate>2016-11-29</prism:coverdate><prism:coverDisplayDate>29 November 2016</prism:coverdisplaydate><prism:copyright>© 2016 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Li, Shanshan</dc:creator><dc:creator>Zhang, Wenda</dc:creator><dc:creator>Yang, Yanwei</dc:creator><dc:creator>Ma, Ting</dc:creator><dc:creator>Guo, Jianpeng</dc:creator><dc:creator>Wang, Shanshan</dc:creator><dc:creator>Yu, Wenying</dc:creator><dc:creator>Kong, Lingyi</dc:creator><dc:description>
                  Constitutive activation of STAT3 has been found in a wide variety of cancers and demonstrated as a very attractive therapeutic target. Disrupting both acetylation and phosphorylation of STAT3 protein was hypothesized to greatly deactivate STAT3, therefore, treating cancers. To demonstrate the hypothesis, two series of novel resveratrol-caffeic acid hybrids were designed aiming to regulate both acetylation and phosphorylation of STAT3 protein, which is also the first report of the synthetic inhibitors simultaneously regulating two biological reactions of STAT3 to our knowledge. Most of these compounds were demonstrated with preferential antitumor activity with low IC50 values against two cancer cell lines. Particularly, compound 7d was found as an excellent STAT3 inhibitor with over 50-fold better potency than resveratrol and caffeic acid. Meanwhile, the novel derivatives significantly inhibited the proliferation and induced the apoptosis of tumor cells. Molecular docking further disclosed the binding modes of STAT3 with the inhibitors. In addition, compound 7d orally and significantly suppressed breast cancer 4T1 xenograft tumor growth in vivo, indicating its great potential as an efficacious drug candidate for human cancer therapy.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Resveratrol</dcterms:subject><dcterms:subject>Acetylated STAT3</dcterms:subject><dcterms:subject>Phosphorylated STAT3</dcterms:subject><dcterms:subject>Caffeic acid</dcterms:subject><dcterms:subject>Antitumor activity</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S022352341630890X" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S022352341630890X" rel="scidir"/></link></coredata><objects><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="82" size="15637">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="201" height="164" size="13187">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="145" height="164" size="23037">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="161" size="21179">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="144" height="164" size="19574">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="72" size="13559">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="158" size="19843">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="194" height="164" size="19439">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="199" height="164" size="11065">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="sc2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="128" size="8872">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-sc2.sml?httpAccept=%2A%2F%2A</object><object ref="sc3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="106" size="8443">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-sc3.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="500" height="188" size="50385">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="387" height="315" size="38624">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="493" height="556" size="106813">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="493" height="363" size="69217">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="809" height="921" size="214445">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="493" height="162" size="33224">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="494" height="356" size="66644">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="387" height="327" size="50812">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="578" height="477" size="56616">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="667" height="389" size="39231">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-sc2.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="533" height="257" size="34791">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-sc3.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2213" height="833" size="254458">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1713" height="1394" size="150844">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2185" height="2465" size="674846">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2185" height="1607" size="426958">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3583" height="4081" size="1319294">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2185" height="720" size="162538">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2187" height="1577" size="352807">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1713" height="1449" size="238323">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2559" height="2110" size="319602">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2953" height="1723" size="228314">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-sc2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2362" height="1139" size="171381">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-sc3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Microsoft Word file" mimetype="application/word" size="48948280">https://api.elsevier.com/content/object/eid/1-s2.0-S022352341630890X-mmc1.docx?httpAccept=%2A%2F%2A</object></objects><scopus-id>84994059894</scopus-id><scopus-eid>2-s2.0-84994059894</scopus-eid><pubmed-id>27783972</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/84994059894" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20161015">2016-10-15</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20161015">2016-10-15</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20161023">2016-10-23</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20161023">2016-10-23</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2017-09-18T10:08:57</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S022352341630890X</xocs:eid>
      <xocs:pii-formatted>S0223-5234(16)30890-X</xocs:pii-formatted>
      <xocs:pii-unformatted>S022352341630890X</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2016.10.028</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.3</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523416X00165</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20170918">2017-09-18T15:25:25.761403-04:00</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20161129</xocs:date-search-begin>
      <xocs:year-nav>2016</xocs:year-nav>
      <xocs:indexeddate epoch="1476570877">2016-10-15T22:34:37.858285Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast grantnumber grantsponsor grantsponsorid highlightsabst orcid primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>124</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>124</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 124</xocs:vol-iss-suppl-text>
      <xocs:sort-order>70</xocs:sort-order>
      <xocs:first-fp>1006</xocs:first-fp>
      <xocs:last-lp>1018</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>1006</xocs:first-page>
         <xocs:last-page>1018</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20161129</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>29 November 2016</xocs:cover-date-text>
      <xocs:cover-date-start>2016-11-29</xocs:cover-date-start>
      <xocs:cover-date-year>2016</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Original articles</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2016 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>DISCOVERYORALAVAILABLERESVERATROLCAFFEICACIDBASEDHYBRIDSINHIBITINGACETYLATEDPHOSPHORYLATEDSTAT3PROTEIN</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>LI</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>S</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>In vitro cell growth inhibitory activity</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>7d</ce:bold> inhibited the STAT3 acetylation at lysine 685 and affected its specific genes expressions</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>7d</ce:bold> inhibited STAT3 tyrosine phosphorylation</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>7d</ce:bold> affected the expressions of STAT3-regulated genes and didn't inhibit STAT1 phosphorylation</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>7d</ce:bold> induced tumor cells apoptosis <ce:italic>in vitro</ce:italic>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>7d</ce:bold> inhibited cancer cells proliferation <ce:italic>in vitro</ce:italic>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.8</xocs:item-toc-label>
               <xocs:item-toc-section-title>Compound <ce:bold>7d</ce:bold> arrested tumor growth <ce:italic>in vivo</ce:italic>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.9</xocs:item-toc-label>
               <xocs:item-toc-section-title>Molecular docking study</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusion</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Experimental section</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedures for the preparation of diethyl 4-nitrobenzylphosphonate (<ce:bold>2</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the preparation of (E)-1,3-dimethoxy-5-(4-nitro- styryl)benzene (<ce:bold>4</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the preparation of (E)-4-(3,5-dimethoxystyryl)aniline (<ce:bold>5</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the preparation of compounds <ce:bold>7a-7o</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>
                        <ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)cinnamamide (<ce:bold>7a</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)-3-(4-methoxyphenyl)acrylamide (<ce:bold>7b</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-3-(3,4-dimethoxyphenyl)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)acrylamide (<ce:bold>7c</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)-3-(3,4,5-trimethoxyphenyl)acrylamide (<ce:bold>7d</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.5</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)-3-(4-hydroxy-3,5-dimethoxyphenyl)ac-rylamide (<ce:bold>7e</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.6</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)-3-(4-(trifluoromethyl)phenyl)acrylami-de (<ce:bold>7f</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.7</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-3-(4-cyanophenyl)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)acrylamide (<ce:bold>7g</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.8</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)-3-(4-nitrophenyl)acrylamide (<ce:bold>7h</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.9</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)-3-(4-fluorophenyl)acrylamide(<ce:bold>7i</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.10</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)-3-(3-fluorophenyl)acrylamide(<ce:bold>7j</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.11</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)-3-(2-fluorophenyl)acrylamide(<ce:bold>7k</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.12</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-3-(2,4-difluorophenyl)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)acrylamide (<ce:bold>7l</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.13</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-3-(4-chlorophenyl)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)acrylamide (<ce:bold>7m</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.14</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-3-(4-bromophenyl)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)acrylamide (<ce:bold>7n</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.15</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)-3-(pyridin-2-yl)acrylamide (<ce:bold>7o</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Procedure for the preparation of compound <ce:bold>10p</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-3-(3,4-dihydroxyphenyl)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)acrylamide (<ce:bold>10p</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure for the preparation of compounds <ce:bold>12a</ce:bold>-<ce:bold>12i</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>4-(3,5-dimethoxystyryl)phenyl cinnamate (<ce:bold>12a</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-4-(3,5-dimethoxystyryl)phenyl 3-(3,4,5-trimethoxyphenyl)acrylate (<ce:bold>12d</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-4-(3,5-dimethoxystyryl)phenyl 3-(4-(trifluoromethyl)phenyl)acrylate (<ce:bold>12f</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-4-(3,5-dimethoxystyryl)phenyl 3-(4-nitrophenyl)acrylate (<ce:bold>12h</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.6.5</xocs:item-toc-label>
                     <xocs:item-toc-section-title>(E)-4-(3,5-dimethoxystyryl)phenyl 3-(4-fluorophenyl)acrylate (<ce:bold>12i</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Cell line and cell culture</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>MTT assay</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Western blot assay</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>Quantitative real-time RT-PCR</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>Cell apoptosis analysis using AV-FITC/PI double-staining assay</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>Cell proliferation assay</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.8</xocs:item-toc-label>
               <xocs:item-toc-section-title>In vivo xenograft tumor assays</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.9</xocs:item-toc-label>
               <xocs:item-toc-section-title>Molecular docking studies</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>GARCIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>2499</xocs:ref-first-fp>
            <xocs:ref-last-lp>2513</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>BOENGLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>172</xocs:ref-first-fp>
            <xocs:ref-last-lp>185</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>798</xocs:ref-first-fp>
            <xocs:ref-last-lp>809</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>DEBNATH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>6645</xocs:ref-first-fp>
            <xocs:ref-last-lp>6668</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1181</xocs:ref-first-fp>
            <xocs:ref-last-lp>1191</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>4402</xocs:ref-first-fp>
            <xocs:ref-last-lp>4412</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>SIVEEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>136</xocs:ref-first-fp>
            <xocs:ref-last-lp>154</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>7765</xocs:ref-first-fp>
            <xocs:ref-last-lp>7769</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>YUAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>269</xocs:ref-first-fp>
            <xocs:ref-last-lp>273</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>11528</xocs:ref-first-fp>
            <xocs:ref-last-lp>11534</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>JANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>218</xocs:ref-first-fp>
            <xocs:ref-last-lp>220</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>NIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>492</xocs:ref-first-fp>
            <xocs:ref-last-lp>500</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>CARBO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>739</xocs:ref-first-fp>
            <xocs:ref-last-lp>743</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>QUIDEAU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>6824</xocs:ref-first-fp>
            <xocs:ref-last-lp>6826</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>KOTHA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>621</xocs:ref-first-fp>
            <xocs:ref-last-lp>629</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>NARDINI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>1098</xocs:ref-first-fp>
            <xocs:ref-last-lp>1105</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>JUNG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>1780</xocs:ref-first-fp>
            <xocs:ref-last-lp>1787</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>300</xocs:ref-first-fp>
            <xocs:ref-last-lp>307</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>ALRIYAMI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>9982</xocs:ref-first-fp>
            <xocs:ref-last-lp>10002</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>LION</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>1292</xocs:ref-first-fp>
            <xocs:ref-last-lp>1295</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>MOTOSHIMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>5001</xocs:ref-first-fp>
            <xocs:ref-last-lp>5014</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>LAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>6089</xocs:ref-first-fp>
            <xocs:ref-last-lp>6104</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>BARONTINI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>809</xocs:ref-first-fp>
            <xocs:ref-last-lp>816</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>DAMBROSIO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>2079</xocs:ref-first-fp>
            <xocs:ref-last-lp>2088</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>MA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>7009</xocs:ref-first-fp>
            <xocs:ref-last-lp>7014</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>6948</xocs:ref-first-fp>
            <xocs:ref-last-lp>6953</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>NIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>7432</xocs:ref-first-fp>
            <xocs:ref-last-lp>7440</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>CHUNG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>6508</xocs:ref-first-fp>
            <xocs:ref-last-lp>6516</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>TAKEDA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>4652</xocs:ref-first-fp>
            <xocs:ref-last-lp>4660</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>MASUDA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>3351</xocs:ref-first-fp>
            <xocs:ref-last-lp>3355</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>KIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>454</xocs:ref-first-fp>
            <xocs:ref-last-lp>465</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>XIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>13972</xocs:ref-first-fp>
            <xocs:ref-last-lp>13984</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>BOATRIGHT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>725</xocs:ref-first-fp>
            <xocs:ref-last-lp>731</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>CONUS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>685</xocs:ref-first-fp>
            <xocs:ref-last-lp>698</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>ZOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>11549</xocs:ref-first-fp>
            <xocs:ref-last-lp>11556</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>DONEPUDI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>543</xocs:ref-first-fp>
            <xocs:ref-last-lp>549</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>KOMINAMI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1825</xocs:ref-first-fp>
            <xocs:ref-last-lp>1840</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>498</xocs:ref-first-fp>
            <xocs:ref-last-lp>507</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>220</xocs:ref-first-fp>
            <xocs:ref-last-lp>227</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>SHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>13</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>SHAIKH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>506</xocs:ref-first-fp>
            <xocs:ref-last-lp>527</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>35242</xocs:ref-first-fp>
            <xocs:ref-last-lp>35250</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>LIX2016X1006</xocs:refkey3>
         <xocs:refkey4lp>LIX2016X1006X1018</xocs:refkey4lp>
         <xocs:refkey4ai>LIX2016X1006XS</xocs:refkey4ai>
         <xocs:refkey5>LIX2016X1006X1018XS</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:self-archiving>
         <xocs:sa-start-date>2018-10-23T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-embargo-status>UnderEmbargo</xocs:sa-embargo-status>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2016 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(16)30890-X</xocs:pii-formatted>
         <xocs:pii-unformatted>S022352341630890X</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S022352341630890X</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2016.10.028</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2017-09-18T15:25:25.761403-04:00</xocs:timestamp>
         <xocs:cover-date-start>2016-11-29</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/MAIN/application/pdf/5195d12c9c8f051550da43f95f42589a/main.pdf</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/MAIN/application/pdf/5195d12c9c8f051550da43f95f42589a/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>2321395</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>13</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S022352341630890X-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/PREVIEW/image/png/6179c3193cc5f83b53c78b5d88ad0e22/main_1.png</xocs:ucs-locator>
                     <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/PREVIEW/image/png/6179c3193cc5f83b53c78b5d88ad0e22/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>56595</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/fx1/THUMBNAIL/image/gif/255df0adb62ef0d21ac56d13b5cfba65/fx1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/fx1/THUMBNAIL/image/gif/255df0adb62ef0d21ac56d13b5cfba65/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>15637</xocs:filesize>
               <xocs:pixel-height>82</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr1/THUMBNAIL/image/gif/b9d1299e0d5d0c3570b32c60089407d7/gr1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr1/THUMBNAIL/image/gif/b9d1299e0d5d0c3570b32c60089407d7/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13187</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>201</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr2/THUMBNAIL/image/gif/8855b27feb17b7cc5b7fe816f05d4e9e/gr2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr2/THUMBNAIL/image/gif/8855b27feb17b7cc5b7fe816f05d4e9e/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>23037</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>145</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr3/THUMBNAIL/image/gif/3512699888bc56293292184b6ee8675b/gr3.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr3/THUMBNAIL/image/gif/3512699888bc56293292184b6ee8675b/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>21179</xocs:filesize>
               <xocs:pixel-height>161</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr4/THUMBNAIL/image/gif/e7d816459e7717b13419dbd48876ebc4/gr4.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr4/THUMBNAIL/image/gif/e7d816459e7717b13419dbd48876ebc4/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>19574</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>144</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr5/THUMBNAIL/image/gif/157f8e06809a7a774c2865557ae90849/gr5.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr5/THUMBNAIL/image/gif/157f8e06809a7a774c2865557ae90849/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13559</xocs:filesize>
               <xocs:pixel-height>72</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr6/THUMBNAIL/image/gif/fd3d0ada93eaec5b2fc6be12b939c067/gr6.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr6/THUMBNAIL/image/gif/fd3d0ada93eaec5b2fc6be12b939c067/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>19843</xocs:filesize>
               <xocs:pixel-height>158</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr7/THUMBNAIL/image/gif/1453e18c70a7663efe3dc5556829aa58/gr7.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr7/THUMBNAIL/image/gif/1453e18c70a7663efe3dc5556829aa58/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>19439</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>194</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/sc1/THUMBNAIL/image/gif/dfe16f269e7ca3f6142a8ae3d8e3c3c3/sc1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/sc1/THUMBNAIL/image/gif/dfe16f269e7ca3f6142a8ae3d8e3c3c3/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11065</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>199</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-sc2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/sc2/THUMBNAIL/image/gif/628f218180aa5107589043be639d6a12/sc2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/sc2/THUMBNAIL/image/gif/628f218180aa5107589043be639d6a12/sc2.sml</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8872</xocs:filesize>
               <xocs:pixel-height>128</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-sc3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/sc3/THUMBNAIL/image/gif/c49c0cbe329b9d3fd0079483faabd1a7/sc3.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/sc3/THUMBNAIL/image/gif/c49c0cbe329b9d3fd0079483faabd1a7/sc3.sml</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8443</xocs:filesize>
               <xocs:pixel-height>106</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/fx1/DOWNSAMPLED/image/jpeg/cce37221bcb89ba1eeef394cceab6555/fx1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/fx1/DOWNSAMPLED/image/jpeg/cce37221bcb89ba1eeef394cceab6555/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>50385</xocs:filesize>
               <xocs:pixel-height>188</xocs:pixel-height>
               <xocs:pixel-width>500</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr1/DOWNSAMPLED/image/jpeg/988f2695c9e0ba43543a593e34f2684f/gr1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr1/DOWNSAMPLED/image/jpeg/988f2695c9e0ba43543a593e34f2684f/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>38624</xocs:filesize>
               <xocs:pixel-height>315</xocs:pixel-height>
               <xocs:pixel-width>387</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr2/DOWNSAMPLED/image/jpeg/79f1c8c46b5a93c45db2f33c97eedf70/gr2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr2/DOWNSAMPLED/image/jpeg/79f1c8c46b5a93c45db2f33c97eedf70/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>106813</xocs:filesize>
               <xocs:pixel-height>556</xocs:pixel-height>
               <xocs:pixel-width>493</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr3/DOWNSAMPLED/image/jpeg/d94ee5a411b941a58e7d8e5bbbf6f474/gr3.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr3/DOWNSAMPLED/image/jpeg/d94ee5a411b941a58e7d8e5bbbf6f474/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>69217</xocs:filesize>
               <xocs:pixel-height>363</xocs:pixel-height>
               <xocs:pixel-width>493</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr4/DOWNSAMPLED/image/jpeg/43ca02a676e8b4c323d76b89429e42e7/gr4.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr4/DOWNSAMPLED/image/jpeg/43ca02a676e8b4c323d76b89429e42e7/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>214445</xocs:filesize>
               <xocs:pixel-height>921</xocs:pixel-height>
               <xocs:pixel-width>809</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr5/DOWNSAMPLED/image/jpeg/2c11577b79ba411a19780bfd8a60db10/gr5.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr5/DOWNSAMPLED/image/jpeg/2c11577b79ba411a19780bfd8a60db10/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>33224</xocs:filesize>
               <xocs:pixel-height>162</xocs:pixel-height>
               <xocs:pixel-width>493</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr6/DOWNSAMPLED/image/jpeg/02421ba83e31fa6cc18f3a8c1df92ce8/gr6.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr6/DOWNSAMPLED/image/jpeg/02421ba83e31fa6cc18f3a8c1df92ce8/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>66644</xocs:filesize>
               <xocs:pixel-height>356</xocs:pixel-height>
               <xocs:pixel-width>494</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr7/DOWNSAMPLED/image/jpeg/7aa30e01019e6873f172b960af98b78c/gr7.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr7/DOWNSAMPLED/image/jpeg/7aa30e01019e6873f172b960af98b78c/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>50812</xocs:filesize>
               <xocs:pixel-height>327</xocs:pixel-height>
               <xocs:pixel-width>387</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/sc1/DOWNSAMPLED/image/jpeg/806eecb6d960ba0d344061137e83b4ab/sc1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/sc1/DOWNSAMPLED/image/jpeg/806eecb6d960ba0d344061137e83b4ab/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>56616</xocs:filesize>
               <xocs:pixel-height>477</xocs:pixel-height>
               <xocs:pixel-width>578</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-sc2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/sc2/DOWNSAMPLED/image/jpeg/506cab86d318d37bf6e31419a2e9a766/sc2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/sc2/DOWNSAMPLED/image/jpeg/506cab86d318d37bf6e31419a2e9a766/sc2.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>39231</xocs:filesize>
               <xocs:pixel-height>389</xocs:pixel-height>
               <xocs:pixel-width>667</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-sc3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/sc3/DOWNSAMPLED/image/jpeg/5de6f62b602a408b76690584bde7409e/sc3.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/sc3/DOWNSAMPLED/image/jpeg/5de6f62b602a408b76690584bde7409e/sc3.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34791</xocs:filesize>
               <xocs:pixel-height>257</xocs:pixel-height>
               <xocs:pixel-width>533</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/fx1/HIGHRES/image/jpeg/de9c54c3d75261c7f599bec0d997aec5/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/fx1/HIGHRES/image/jpeg/de9c54c3d75261c7f599bec0d997aec5/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>254458</xocs:filesize>
               <xocs:pixel-height>833</xocs:pixel-height>
               <xocs:pixel-width>2213</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr1/HIGHRES/image/jpeg/bbd4edf1f0c7baf02896f007f4eb613d/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr1/HIGHRES/image/jpeg/bbd4edf1f0c7baf02896f007f4eb613d/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>150844</xocs:filesize>
               <xocs:pixel-height>1394</xocs:pixel-height>
               <xocs:pixel-width>1713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr2/HIGHRES/image/jpeg/e830b0b1e63828953c6f02c7bf1e89e0/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr2/HIGHRES/image/jpeg/e830b0b1e63828953c6f02c7bf1e89e0/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>674846</xocs:filesize>
               <xocs:pixel-height>2465</xocs:pixel-height>
               <xocs:pixel-width>2185</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr3/HIGHRES/image/jpeg/8e7d0c15bf122a6f66952a97a9cbe888/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr3/HIGHRES/image/jpeg/8e7d0c15bf122a6f66952a97a9cbe888/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>426958</xocs:filesize>
               <xocs:pixel-height>1607</xocs:pixel-height>
               <xocs:pixel-width>2185</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr4/HIGHRES/image/jpeg/474e476b7c9524fac1c1a46aadb45a2f/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr4/HIGHRES/image/jpeg/474e476b7c9524fac1c1a46aadb45a2f/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1319294</xocs:filesize>
               <xocs:pixel-height>4081</xocs:pixel-height>
               <xocs:pixel-width>3583</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr5/HIGHRES/image/jpeg/2af53d8439d3f4501a3afc13e95f1935/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr5/HIGHRES/image/jpeg/2af53d8439d3f4501a3afc13e95f1935/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>162538</xocs:filesize>
               <xocs:pixel-height>720</xocs:pixel-height>
               <xocs:pixel-width>2185</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr6/HIGHRES/image/jpeg/d974639aadf8b42edc46da1c92a82f51/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr6/HIGHRES/image/jpeg/d974639aadf8b42edc46da1c92a82f51/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>352807</xocs:filesize>
               <xocs:pixel-height>1577</xocs:pixel-height>
               <xocs:pixel-width>2187</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/gr7/HIGHRES/image/jpeg/84a72a3bff3bb70bb17f7746afe4feb9/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/gr7/HIGHRES/image/jpeg/84a72a3bff3bb70bb17f7746afe4feb9/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>238323</xocs:filesize>
               <xocs:pixel-height>1449</xocs:pixel-height>
               <xocs:pixel-width>1713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/sc1/HIGHRES/image/jpeg/e6279ec50b7dd8b94138d62f27e5fb9f/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/sc1/HIGHRES/image/jpeg/e6279ec50b7dd8b94138d62f27e5fb9f/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>319602</xocs:filesize>
               <xocs:pixel-height>2110</xocs:pixel-height>
               <xocs:pixel-width>2559</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-sc2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/sc2/HIGHRES/image/jpeg/23bcec5e2b78c7949b8484a21c65a32f/sc2_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/sc2/HIGHRES/image/jpeg/23bcec5e2b78c7949b8484a21c65a32f/sc2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>228314</xocs:filesize>
               <xocs:pixel-height>1723</xocs:pixel-height>
               <xocs:pixel-width>2953</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-sc3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/sc3/HIGHRES/image/jpeg/50d3893b699781213ae2fec42de83020/sc3_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/sc3/HIGHRES/image/jpeg/50d3893b699781213ae2fec42de83020/sc3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>171381</xocs:filesize>
               <xocs:pixel-height>1139</xocs:pixel-height>
               <xocs:pixel-width>2362</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352341630890X-mmc1.docx</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352341630890X/mmc1/MAIN/application/vnd.openxmlformats-officedocument.wordprocessingml.document/9fded63e481614f9de23325b517e7124/mmc1.docx</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S022352341630890X/mmc1/MAIN/application/vnd.openxmlformats-officedocument.wordprocessingml.document/9fded63e481614f9de23325b517e7124/mmc1.docx</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.docx</xocs:filename>
               <xocs:extension>docx</xocs:extension>
               <xocs:filesize>48948280</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.4" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>8993</aid>
            <ce:pii>S0223-5234(16)30890-X</ce:pii>
            <ce:doi>10.1016/j.ejmech.2016.10.028</ce:doi>
            <ce:copyright type="full-transfer" year="2016">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Structures of resveratrol, caffeic acid and resveratrol-caffeic acid hybrids.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0020">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:type="simple" xlink:href="pii:S022352341630890X/gr1"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Compound <ce:bold>7d</ce:bold> inhibited STAT3 activation. (A) p-STAT3, Ac-STAT3 and total STAT3 protein expressions in MDA-MB-231 and HT-29 cell lines by western blot analysis using GAPDH as a control. (B) Compound <ce:bold>7d</ce:bold> inhibited STAT3 acetylation in MDA-MB-231 cells for 48 h performed by western blot analysis. (C) Quantitative real-time RT-PCR was applied to assess the effect of compound <ce:bold>7d</ce:bold> on the mRNA expressions of STAT3 acetylation targets. (D) Compound 7 d inhibited STAT3 tyrosine phosphorylation in MDA-MB-231 cells for 48 h by western blot analysis. Bars represent means ± SD of three independent experiments.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0025">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:type="simple" xlink:href="pii:S022352341630890X/gr2"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Compound <ce:bold>7d</ce:bold> affected the expressions of STAT3-regulated genes and didn't inhibit STAT1 phosphorylation. (A) Western blot results of the expression of STAT3 upstream and downstream genes affected by compound <ce:bold>7d</ce:bold>. (B) The effect of compound <ce:bold>7d</ce:bold> on the mRNA expressions of STAT3 targets was assessed by Quantitative real-time RT-PCR. Data were normalized to the expression of GAPDH. Shown are means ± SD (n = 3). (C) The effect of compound <ce:bold>7d</ce:bold> on STAT1 protein expression by western blot analysis using GAPDH as a control.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0030">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:type="simple" xlink:href="pii:S022352341630890X/gr3"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">Compound <ce:bold>7d</ce:bold> induced tumor cells apoptosis <ce:italic>in vitro</ce:italic>. (A) The AV-FITC/PI double staining assay was used to analyze the compound <ce:bold>7d</ce:bold> (A, B, C, D, E, F mean 0, 1, 2, 5, 8, 10 μM) induced apoptosis in MDA-MB 231 cells detected by flow cytometry. (B) Percent of MDA-MB-231 cells undergoing apoptosis after treatment with 7 d for 48 h. Early apoptosis: AV positive but PI negative; late apoptosis: AV positive and PI positive. Data are the mean value ± SD obtained from three independent experiments. (C) Western blot analysis with antibodies specific for Cleaved Caspase-8, Cleaved Caspase-9, Cleaved Caspase-3 and the house keeping protein GAPDH in MDA-MB-231 cells incubated with compound <ce:bold>7d</ce:bold> for 48 h.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0035">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:type="simple" xlink:href="pii:S022352341630890X/gr4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">Compound <ce:bold>7d</ce:bold> inhibited cancer cells proliferation <ce:italic>in vitro</ce:italic>. Colony forming assay was implemented to assess the anti-proliferative activity of the compound <ce:bold>7d</ce:bold> with respect to MDA-MB 231 cells.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0040">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:type="simple" xlink:href="pii:S022352341630890X/gr5"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">Compound <ce:bold>7d</ce:bold> arrested tumor growth <ce:italic>in vivo</ce:italic>. (A) The weight of tumor tissues of treated and control mice. (B) The tumor growth inhibitory rates of compound <ce:bold>7d</ce:bold> (10 mg/kg, 20 mg/kg) and doxorubicin as a positive control. (C) The body weight changes of treated and control mice. Data represented the means ± SD of six independent experiments. (D) The levels of p-STAT3 and STAT3 in the tumor tissues of treated and control mice determined by Western blot.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0045">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:type="simple" xlink:href="pii:S022352341630890X/gr6"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">Molecular docking model of compound <ce:bold>7d</ce:bold> with STAT3 performed by the Autodock4.2. STAT3 protein was represented as white ribbon. Compound <ce:bold>7d</ce:bold> was displayed by purple stick. Hydrogen bonds were represented by green dashes. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0050">Fig. 7</ce:alt-text>
               <ce:link locator="gr7" xlink:type="simple" xlink:href="pii:S022352341630890X/gr7"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">Synthesis of compound <ce:bold>7a-7o</ce:bold>: (i) P(OEt)<ce:inf loc="post">3</ce:inf>, reflux, 40 min; (ii) dry DMF, sodium methoxide, 0 °C to r.t., overnight; (iii) EtOAc, tin (II) chloride dehydrate, reflux, 5 h; (iv) CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, HATU, <ce:italic>N</ce:italic>,<ce:italic>N</ce:italic>-diisopropylethylamine, r.t., overnight.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0055">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:type="simple" xlink:href="pii:S022352341630890X/sc1"/></ce:link>
            </ce:figure>
            <ce:figure id="sch2">
               <ce:label>Scheme 2</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">Synthesis of compound <ce:bold>10p</ce:bold>: (i) CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, pyridine, acetic anhydride, r.t., 8 h; (ii) CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, HATU, <ce:italic>N</ce:italic>,<ce:italic>N</ce:italic>-diisopropylethylamine, r.t., overnight; (iii) ethanol, dilute sulfuric acid, reflux, 2 h.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0060">Scheme 2</ce:alt-text>
               <ce:link locator="sc2" xlink:type="simple" xlink:href="pii:S022352341630890X/sc2"/></ce:link>
            </ce:figure>
            <ce:figure id="sch3">
               <ce:label>Scheme 3</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0055" view="all">Synthesis of compound <ce:bold>12a–12i</ce:bold>: CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, HATU, <ce:italic>N,N</ce:italic>-diisopropylet- hylamine, r.t., overnight.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0065">Scheme 3</ce:alt-text>
               <ce:link locator="sc3" xlink:type="simple" xlink:href="pii:S022352341630890X/sc3"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl1" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="tspara0010" view="all">Structural features, inhibition activities [IC<ce:inf loc="post">50</ce:inf> (μM)] of compounds <ce:bold>7a-7o</ce:bold>, <ce:bold>10p</ce:bold> and <ce:bold>12a-12i</ce:bold> against HT29 and MDA-MB 231 cells.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0070">Table 1</ce:alt-text>
               <tgroup cols="4">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1">Compounds</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1">R</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col3" nameend="col4">IC<inf loc="post">50</inf>(μM)<cross-ref refid="tbl1fna" id="crosref0190">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">HT29</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MDA-MB 231</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">RES<cross-ref refid="tbl1fnb" id="crosref0195">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3,5,4′-OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">CaA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3,4-OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>100</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>7a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.75 ± 0.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.01 ± 0.61</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>7b</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.96 ± 0.34</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.23 ± 0.22</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>7c</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3,4-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.96 ± 0.09</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">7.74 ± 1.06</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>7d</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3,4,5-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.82 ± 0.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.14 ± 0.14</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>7e</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3,5-OCH<inf loc="post">3,</inf> 4-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.08 ± 0.28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">7.13 ± 0.39</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>7f</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.78 ± 0.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.52 ± 0.11</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>7g</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-CN</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.32 ± 0.18</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">7.74 ± 0.71</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>7h</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">10.65 ± 0.35</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">11.70 ± 1.38</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>7i</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">11.61 ± 0.64</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">9.39 ± 0.65</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>7j</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">16.76 ± 0.58</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">17.30 ± 1.13</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>7k</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.82 ± 0.10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.38 ± 0.55</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>7l</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2,4-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">18.05 ± 1.17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>20</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>7m</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">10.29 ± 0.74</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">14.06 ± 0.92</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>7n</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.26 ± 0.19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">6.16 ± 0.48</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>7o</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H, C<inf loc="post">2</inf>=N<cross-ref refid="tbl1fnc" id="crosref0200">
                              <sup loc="post">c</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">6.12 ± 1.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.40 ± 0.74</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>10p</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3,4-OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.56 ± 0.04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.23 ± 0.22</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>12a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">9.05 ± 0.85</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">9.81 ± 1.06</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>12d</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3,4,5-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.91 ± 0.19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.08 ± 0.37</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>12f</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">9.09 ± 0.61</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">6.91 ± 0.96</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>12h</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>20</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">17.99 ± 1.52</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>12i</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">7.77 ± 0.42</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">6.21 ± 1.03</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl1fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0010" view="all">IC<ce:inf loc="post">50</ce:inf>: 50% inhibitory concentration (means ± SD of three experiments).</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl1fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0015" view="all">Used as a positive control.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl1fnc">
                  <ce:label>c</ce:label>
                  <ce:note-para id="ntpara0020" view="all">C ring of compound <ce:bold>7o</ce:bold> is the substituted pyridine.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Research paper</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S022352341630890X-7a4d56a29ffe88d852538cc483767949">
                  <ce:given-name>Shanshan</ce:given-name>
                  <ce:surname>Li</ce:surname>
               </ce:author>
               <ce:author id="au2" author-id="S022352341630890X-2e90297f20cc85a4bba96283317d4b1d">
                  <ce:given-name>Wenda</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
               </ce:author>
               <ce:author id="au3" author-id="S022352341630890X-e069320d2a205a7ed8f48b6aaa329119">
                  <ce:given-name>Yanwei</ce:given-name>
                  <ce:surname>Yang</ce:surname>
               </ce:author>
               <ce:author id="au4" author-id="S022352341630890X-39ecd4b410f10ed16e10a248f3453bff">
                  <ce:given-name>Ting</ce:given-name>
                  <ce:surname>Ma</ce:surname>
               </ce:author>
               <ce:author id="au5" author-id="S022352341630890X-ff1b91ef1962d9c0f1403f22a5d49a4d">
                  <ce:given-name>Jianpeng</ce:given-name>
                  <ce:surname>Guo</ce:surname>
               </ce:author>
               <ce:author id="au6" author-id="S022352341630890X-da1412673f4c8c3d7b83f7570990afae">
                  <ce:given-name>Shanshan</ce:given-name>
                  <ce:surname>Wang</ce:surname>
               </ce:author>
               <ce:author id="au7" author-id="S022352341630890X-d1cf9a947be835fd95e9f5d003e1151d">
                  <ce:given-name>Wenying</ce:given-name>
                  <ce:surname>Yu</ce:surname>
                  <ce:cross-ref refid="cor2" id="crosref0010">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au8" orcid="0000-0002-4791-8615" author-id="S022352341630890X-6dcd0171bf7f28d6f49075140d5a7fe1">
                  <ce:given-name>Lingyi</ce:given-name>
                  <ce:surname>Kong</ce:surname>
                  <ce:cross-ref refid="cor1" id="crosref0015">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1">
                  <ce:textfn>State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Lane, Nanjing 210009, People's Republic of China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>State Key Laboratory of Natural Medicines</sa:organization>
                     <sa:organization>Department of Natural Medicinal Chemistry</sa:organization>
                     <sa:organization>China Pharmaceutical University</sa:organization>
                     <sa:address-line>24 Tong Jia Lane</sa:address-line>
                     <sa:city>Nanjing</sa:city>
                     <sa:postal-code>210009</sa:postal-code>
                     <sa:country>People's Republic of China</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
            </ce:author-group>
            <ce:date-received day="2" month="8" year="2016"/></ce:date-received>
            <ce:date-revised day="2" month="10" year="2016"/></ce:date-revised>
            <ce:date-accepted day="14" month="10" year="2016"/></ce:date-accepted>
            <ce:abstract xml:lang="en" id="abs0010" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">Constitutive activation of STAT3 has been found in a wide variety of cancers and demonstrated as a very attractive therapeutic target. Disrupting both acetylation and phosphorylation of STAT3 protein was hypothesized to greatly deactivate STAT3, therefore, treating cancers. To demonstrate the hypothesis, two series of novel resveratrol-caffeic acid hybrids were designed aiming to regulate both acetylation and phosphorylation of STAT3 protein, which is also the first report of the synthetic inhibitors simultaneously regulating two biological reactions of STAT3 to our knowledge. Most of these compounds were demonstrated with preferential antitumor activity with low IC<ce:inf loc="post">50</ce:inf> values against two cancer cell lines. Particularly, compound <ce:bold>7d</ce:bold> was found as an excellent STAT3 inhibitor with over 50-fold better potency than resveratrol and caffeic acid. Meanwhile, the novel derivatives significantly inhibited the proliferation and induced the apoptosis of tumor cells. Molecular docking further disclosed the binding modes of STAT3 with the inhibitors. In addition, compound <ce:bold>7d</ce:bold> orally and significantly suppressed breast cancer 4T1 xenograft tumor growth <ce:italic>in vivo</ce:italic>, indicating its great potential as an efficacious drug candidate for human cancer therapy.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">Compound <ce:bold>7d</ce:bold> inhibited acetylated and phosphorylated STAT3 activation to exert antitumor activity.<ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text role="short" id="alttext0010">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:type="simple" xlink:href="pii:S022352341630890X/fx1"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords xml:lang="en" id="kwrds0010" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Resveratrol</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Acetylated STAT3</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Phosphorylated STAT3</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Caffeic acid</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>Antitumor activity</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0030" view="all">Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic protein that plays important roles in oncogenic signaling pathways <ce:cross-refs refid="bib1 bib2 bib3" id="crosrefs0010">[1–3]</ce:cross-refs>. Constitutive activation of STAT3 has been found in a wide variety of cancers, including breast cancer, colon cancer, and other cancers, promoting it as a very attractive therapeutic target <ce:cross-refs refid="bib4 bib5" id="crosrefs0015">[4,5]</ce:cross-refs>.</ce:para>
                  <ce:para id="p0035" view="all">Cytokines, hormones, or growth factors bind to the cell membrane receptors leading to the activation of the receptors which then recruit the STAT3 protein <ce:cross-ref refid="bib6" id="crosref0020">[6]</ce:cross-ref>, and thus cause the phosphorylation of STAT3 at tyrosine 705 residue (Tyr705). Two phosphorylated STAT3 proteins form homo-dimeric activated transcription factor complex through reciprocal binding of pTyr-SH2 domains. The p-STAT3 dimers translocate to the nucleus, where they bind to DNA and induce target genes expressions, such as Bcl-2, Cyclin D1 <ce:cross-refs refid="bib4 bib7" id="crosrefs0020">[4,7]</ce:cross-refs>. Apart from STAT3 phosphorylation at Tyr705, STAT3 is also acetylated at lysine 685 (Lys685). Converting Lys685 to arginine has been revealed to disrupt STAT3 dimerization, consequently abrogate STAT3 DNA-binding and transcriptional activation of oncogenes responding to cytokine stimulation <ce:cross-ref refid="bib8" id="crosref0025">[8]</ce:cross-ref>. Accordingly, acetylation of STAT3 is critical for stabling dimers, heightening transcription of cell growth-related genes, and promoting cell cycle progression <ce:cross-refs refid="bib9 bib10" id="crosrefs0025">[9,10]</ce:cross-refs>. Due to weak activity, significant toxicity, or poor bioavailability, none of STAT3 inhibitors reached the market yet. Therefore, discovery of novel potent and druggable STAT3 inhibitors is still highly valuable. Currently most of the known STAT3 inhibitors focus on the disruption of STAT3 phosphorylation and dimerization. One exception is resveratrol (RES) which targets on the acetylation of STAT3 and greatly diminishes the STAT3 activation <ce:cross-refs refid="bib11 bib12" id="crosrefs0030">[11,12]</ce:cross-refs>. Herein, we raised a hypothesis that inhibitor targeting both acetylated and phosphorylated STAT3 might significantly enhance its activity for chemoprevention and cancer therapy.</ce:para>
                  <ce:para id="p0040" view="all">Natural products extracted from the food resources on account of their low toxicity and extensive application are excellent candidates that can be employed in designing anticancer drugs. Among them, RES, a naturally occurring phytoalexin abundant in red grapes and grape products, is one of the most famous natural product with anticancer, anti-oxidation and anti-inflammatory activities <ce:cross-refs refid="bib11 bib13 bib14" id="crosrefs0035">[11,13,14]</ce:cross-refs>, which significantly inhibits STAT3 acetylation. Besides, RES inhibits Src tyrosine kinase and thereby blocks constitutive STAT3 activation in malignant cells <ce:cross-ref refid="bib15" id="crosref0030">[15]</ce:cross-ref>. Another dietary agent is caffeic acid (CaA), which is a phenolic compound primarily found in food plants <ce:cross-ref refid="bib16" id="crosref0035">[16]</ce:cross-ref>. It suppresses STAT3 phosphorylation to retard tumor growth <ce:cross-refs refid="bib7 bib17" id="crosrefs0040">[7,17]</ce:cross-refs>. The antitumor activity of a good deal of natural and synthetic compounds is also increased when the caffeic acid residues are introduced in the form of amides or esters <ce:cross-ref refid="bib18" id="crosref0040">[18]</ce:cross-ref>. Low toxicity makes these natural products extensively employed in cancer therapy.</ce:para>
                  <ce:para id="p0045" view="all">Thus, two series of resveratrol-caffeic acid hybrids (<ce:cross-ref refid="fig1" id="crosref0045">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>) were designed, synthesized and biologically evaluated. The hybrids were validated to block both the acetylation and phosphorylation of STAT3, to inhibit malignancy proliferation and to induce the apoptosis of cancer cells. Furthermore, the IC<ce:inf loc="post">50</ce:inf> value of compound <ce:bold>7d</ce:bold> was approximately 50-fold more active than RES. And it orally significantly suppressed breast cancer cells 4T1 xenograft tumor growth <ce:italic>in vivo</ce:italic>. In order to identify the possible binding mode, molecular docking studies were consequently performed. The results demonstrated the feasibility and efficiency of the strategy inhibiting two sites of the single STAT3 target for cancer therapy.</ce:para>
               </ce:section>
               <ce:section id="sec2" role="results" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Results and discussion</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">Chemistry</ce:section-title>
                     <ce:para id="p0050" view="all">The synthetic pathways of target compounds were outlined in <ce:cross-refs refid="sch1 sch2 sch3" id="crosrefs0045">Schemes 1–3</ce:cross-refs>
                        <ce:float-anchor refid="sch1"/></ce:float-anchor>
                        <ce:float-anchor refid="sch2"/></ce:float-anchor>
                        <ce:float-anchor refid="sch3"/></ce:float-anchor>. Firstly, the phosphonic acid precursor <ce:bold>(2)</ce:bold> was prepared from the commercially available starting material 4-Nitrobenzyl bromide <ce:bold>(1)</ce:bold> by the Arbuzov reaction <ce:cross-ref refid="bib19" id="crosref0050">[19]</ce:cross-ref>, which was further reacted with 3,5-dimethoxybenzaldehyde <ce:bold>(3)</ce:bold> to offer compound <ce:bold>4</ce:bold> by the Horner-Emmons-Wadsworth olefination as described by Lion et al. <ce:cross-ref refid="bib20" id="crosref0055">[20]</ce:cross-ref>. The nitro group of compound <ce:bold>4</ce:bold> was reduced to the amine group by tin (II) chloride dihydrate under nitrogen and was converted to the respective (<ce:italic>E</ce:italic>)-4-(3,5-dimethoxystyryl) aniline <ce:bold>(5)</ce:bold> 
                        <ce:cross-ref refid="bib21" id="crosref0060">[21]</ce:cross-ref>. Finally, caffeic acid derivatives <ce:bold>6a-6o</ce:bold> were reacted with intermediate <ce:bold>5</ce:bold> to give the target compounds <ce:bold>7a-7o</ce:bold> in good yields <ce:cross-ref refid="bib22" id="crosref0065">[22]</ce:cross-ref>. Except for <ce:bold>6p</ce:bold>, which was substituted with two hydroxyl groups, <ce:bold>6p</ce:bold> was first protected with the acetyl groups and then deprotected. Finally, the target compound <ce:bold>10p</ce:bold> was synthesized as shown in <ce:cross-ref refid="sch2" id="crosref0070">Scheme 2</ce:cross-ref> 
                        <ce:cross-refs refid="bib23 bib24 bib25" id="crosrefs0050">[23–25]</ce:cross-refs>. For the structure-activity relationship (SAR) study, compound <ce:bold>12a-12i</ce:bold> possessing ester linkage were also synthesized (<ce:cross-ref refid="sch3" id="crosref0075">Scheme 3</ce:cross-ref>).</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">In vitro cell growth inhibitory activity</ce:section-title>
                     <ce:para id="p0055" view="all">To explore the SAR, we evaluated the <ce:italic>in vitro</ce:italic> antitumor activity of the designed derivatives against human colonic carcinoma HT29 and human breast cancer MDA-MB-231 cell lines with RES and CaA as the positive controls using MTT assay. The IC<ce:inf loc="post">50</ce:inf> results of <ce:bold>7a-7o, 10p</ce:bold> and <ce:bold>12a-12i</ce:bold> were illustrated in <ce:cross-ref refid="tbl1" id="crosref0080">Table 1</ce:cross-ref>
                        <ce:float-anchor refid="tbl1"/></ce:float-anchor>. Most compounds had lower IC<ce:inf loc="post">50</ce:inf> values than the positive controls in the two cell lines. Compounds <ce:bold>7c</ce:bold> (IC<ce:inf loc="post">50</ce:inf> = 0.96 μM for HT29) and <ce:bold>7d</ce:bold> (IC<ce:inf loc="post">50</ce:inf> = 2.14 μM for MDA-MB-231) had the most potent antitumor activity among all. In comparison to the positive control RES (IC<ce:inf loc="post">50</ce:inf> > 100 μM for HT29 and MDA-MB-231), both compounds were over 50-fold more active. In addition, HT29 cell line displayed higher sensitivity than MDA-MB-231 cell line for most compounds.</ce:para>
                     <ce:para id="p0060" view="all">In general, the compounds which consist of amide linker (<ce:bold>7a-7o</ce:bold>) showed superior antitumor activities to compounds <ce:bold>12a-12i</ce:bold> possessing ester linkage. In addition, stronger electron-withdrawing substitutes (except trifluoromethyl group) had lower antitumor activities than electron-donating groups. Compounds with the methoxy group (such as <ce:bold>7c, 7d, 7e</ce:bold> and <ce:bold>12d</ce:bold>) or trifluoromethyl group (<ce:bold>7f, 12f</ce:bold>) exhibited strong anticancer activity. Moreover, the antitumor activity was significantly improved with the increased number of methoxyl group (<ce:bold>7b, 7c, 7d</ce:bold>). However, halogen substituents (<ce:bold>7i, 7m, 7n</ce:bold> and <ce:bold>12i</ce:bold>) resulted in a remarkable decrease of antitumor activity.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0050">Compound <ce:bold>7d</ce:bold> inhibited the STAT3 acetylation at lysine 685 and affected its specific genes expressions</ce:section-title>
                     <ce:para id="p0065" view="all">To verify that STAT3 was the target of the designed compounds, western blot assays were performed to detect the abundances of acetylated and phosphorylated STAT3 (Ac-STAT3, p-STAT3). Because MDA-MB-231 cell line exhibits higher levels of acetylated STAT3, phosphorylated STAT3 and total STAT3 expressions than that of HT29 cell line (<ce:cross-ref refid="fig2" id="crosref0085">Fig. 2</ce:cross-ref>
                        <ce:float-anchor refid="fig2"/></ce:float-anchor>A), MDA-MB-231 cell line was selected to study the antitumor mechanism of compound <ce:bold>7d</ce:bold>. Exposing MDA-MB-231 cells to compound <ce:bold>7d</ce:bold> (1–5 μM) for 48 h led to dose-dependent inhibition of STAT3 acetylation at Lys685 residue, but had no effect on total STAT3 (<ce:cross-ref refid="fig2" id="crosref0090">Fig. 2</ce:cross-ref>B).</ce:para>
                     <ce:para id="p0070" view="all">Mutating Lys685 of STAT3 is known to inhibit STAT3 acetylation. The mutation also up-regulates the expressions of several key tumor-suppressor genes in human cancers, including p53, PTPN6 (SHP-1), CDKN2A and DLEC1 <ce:cross-refs refid="bib8 bib26 bib27" id="crosrefs0055">[8,26,27]</ce:cross-refs>. Quantitative real-time RT-PCR was applied to assess the effect of compound <ce:bold>7d</ce:bold> on the mRNA expressions of the acetylated STAT3 downstream genes. We evaluated the mRNA levels of PTPN6 (SHP-1), CDKN2A and DLEC1 in MDA-MB-231 cells treated with compound <ce:bold>7d</ce:bold> for 48 h. Results indicated that compound <ce:bold>7d</ce:bold> increased the expressions of these tumor-suppressor genes which were related to STAT3 acetylation at Lys685 (<ce:cross-ref refid="fig2" id="crosref0095">Fig. 2</ce:cross-ref>C), thereby further demonstrated that <ce:bold>7d</ce:bold> inhibited STAT3 acetylation.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.4" view="all">
                     <ce:label>2.4</ce:label>
                     <ce:section-title id="sectitle0055">Compound <ce:bold>7d</ce:bold> inhibited STAT3 tyrosine phosphorylation</ce:section-title>
                     <ce:para id="p0075" view="all">The effect of compound <ce:bold>7d</ce:bold> (1–5 μM) on STAT3 phosphorylation at tyrosine 705 residue was also assessed in MDA-MB-231 cancer cells for 48 h. As shown in <ce:cross-ref refid="fig2" id="crosref0100">Fig. 2</ce:cross-ref>D, compound <ce:bold>7d</ce:bold> markedly decreased the phospho-Tyr705 STAT3 in a dose-dependent manner without affected the total STAT3, indicating that compound <ce:bold>7d</ce:bold> selectively decreased the level of p-STAT3 which was not due to a constitutional decrease of total STAT3 expression.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.5" view="all">
                     <ce:label>2.5</ce:label>
                     <ce:section-title id="sectitle0060">Compound <ce:bold>7d</ce:bold> affected the expressions of STAT3-regulated genes and didn't inhibit STAT1 phosphorylation</ce:section-title>
                     <ce:para id="p0080" view="all">Src proteins can phosphorylate certain tyrosine residues in the intracellular domain of the receptors. Then, the receptors are induced to form the binding sites for STAT3 <ce:cross-ref refid="bib4" id="crosref0105">[4]</ce:cross-ref>. The Erk family of mitogen-activated protein kinases specifically stimulates the serine phosphorylation of STAT3 responding to growth factors <ce:cross-ref refid="bib28" id="crosref0110">[28]</ce:cross-ref>. Additionally, Persistent active STAT3 activates the transcription of several oncogenes, such as Cyclin D1, involved in cell cycle progression, and anti-apoptotic gene Bcl-2, related to the caspase-dependent pathways <ce:cross-refs refid="bib29 bib30" id="crosrefs0060">[29,30]</ce:cross-refs>. To investigate whether compound <ce:bold>7d</ce:bold> affects the expressions of these genes, we evaluated the effects of <ce:bold>7d</ce:bold> on <ce:italic>p</ce:italic>-Src, <ce:italic>p</ce:italic>-Erk, Bcl-2 and Cyclin D1 by immunoblotting analysis for 48 h. Results suggested that compound <ce:bold>7d</ce:bold> had slight effects on the levels of <ce:italic>p</ce:italic>-Src and <ce:italic>p</ce:italic>-Erk, while <ce:bold>7d</ce:bold> markedly suppressed the expressions of STAT3 downstream proteins, Bcl-2 and Cyclin D1 (<ce:cross-ref refid="fig3" id="crosref0115">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="fig3"/></ce:float-anchor>A). The effect of compound <ce:bold>7d</ce:bold> on the mRNA expressions of STAT3 target genes was also assessed by quantitative real-time RT-PCR. Consistent with western blot analysis, the mRNA levels of Bcl-2 and Cyclin D1 were significantly decreased by compound <ce:bold>7d</ce:bold> in MDA-MB-231 cells (<ce:cross-ref refid="fig3" id="crosref0120">Fig. 3</ce:cross-ref>B). These indicated that compound <ce:bold>7d</ce:bold> inhibited the expression of p-STAT3 (Y705) and consequently suppressed STAT3 target genes, whereas not correlated with upstream <ce:italic>p</ce:italic>-Src or bypass <ce:italic>p</ce:italic>-Erk.</ce:para>
                     <ce:para id="p0085" view="all">STAT1, a tumor suppressor protein, is another member of the STATs family. It can inhibit tumor cell proliferation and induce tumor cell apoptosis <ce:cross-ref refid="bib31" id="crosref0125">[31]</ce:cross-ref>. As shown in <ce:cross-ref refid="fig3" id="crosref0130">Fig. 3</ce:cross-ref>C by western blot assays, compound <ce:bold>7d</ce:bold> had no effect on the extent of STAT1 phosphorylation. Thus, certain selectivity of compound <ce:bold>7d</ce:bold> for STAT3 inhibition was proved.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.6" view="all">
                     <ce:label>2.6</ce:label>
                     <ce:section-title id="sectitle0065">Compound <ce:bold>7d</ce:bold> induced tumor cells apoptosis <ce:italic>in vitro</ce:italic>
                     </ce:section-title>
                     <ce:para id="p0090" view="all">Once the apoptosis of cancer cells occurs, the damage to normal cells would be generally eliminated. In order to test whether our compounds inhibited tumor growth by inducing apoptosis, we studied the anticancer activity of compound <ce:bold>7d</ce:bold> by Annexin V-FITC/PI staining assay using flow cytometry <ce:cross-ref refid="bib32" id="crosref0135">[32]</ce:cross-ref>. MDA-MB-231 cells were cultured <ce:italic>in vitro</ce:italic> treated with gradient concentrations of <ce:bold>7d</ce:bold> for 48 h. According to the analysis, the induced apoptosis rates (early and late apoptosis) at 1, 2, 5, 8 and 10 μM were 9.0%, 11.2%, 20.9%, 43.3% and 85.2% <ce:italic>versus</ce:italic> control 3.0% (<ce:cross-ref refid="fig4" id="crosref0140">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="fig4"/></ce:float-anchor>A). In addition, Caspase-8 and Caspase-9 served as initiators of the activation and onset of apoptosis <ce:cross-refs refid="bib33 bib34" id="crosrefs0065">[33,34]</ce:cross-refs>. The executioner Caspase-3 can be activated after the cleavage by Caspase-9, which is a protease of the intrinsic apoptotic pathway activated in the mitochondrial damage <ce:cross-ref refid="bib35" id="crosref0145">[35]</ce:cross-ref>. Also, Caspase-3 can be activated by Caspase-8 which participates in receptor-mediated apoptosis <ce:cross-refs refid="bib36 bib37" id="crosrefs0070">[36,37]</ce:cross-refs>. In order to determine how <ce:bold>7d</ce:bold> induced the apoptosis in MDA-MB-231 cells, we examined the expressions of caspase-related proteins by western blots. Not surprisingly, treatment with <ce:bold>7d</ce:bold> markedly induced cleavage of Caspase-9 and Caspase-3 in concentration dependent manner, while had slight effects on the levels of Cleaved Caspase-8. Thus, compound <ce:bold>7d</ce:bold> induced the Cleaved Caspase-9 to activate downstream Caspase-3, thereby leading to cell death by mitochondria mediated apoptosis in human breast cancer cells MDA-MB-231. And it mainly occurred in early apoptosis (<ce:cross-ref refid="fig4" id="crosref0150">Fig. 4</ce:cross-ref>B and C). These indicated that compound <ce:bold>7d</ce:bold> could induce the apoptosis of MDA-MB-231 cells in a dose-dependent manner through activating the caspase-dependent pathway. The apoptosis was regulated by the deactivation of STAT3 protein.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.7" view="all">
                     <ce:label>2.7</ce:label>
                     <ce:section-title id="sectitle0070">Compound <ce:bold>7d</ce:bold> inhibited cancer cells proliferation <ce:italic>in vitro</ce:italic>
                     </ce:section-title>
                     <ce:para id="p0095" view="all">Colony forming assay was implemented to assess the anti-proliferative activity of the compound <ce:bold>7d</ce:bold> with respect to MDA-MB-231 cells. As depicted in <ce:cross-ref refid="fig5" id="crosref0155">Fig. 5</ce:cross-ref>
                        <ce:float-anchor refid="fig5"/></ce:float-anchor>, there was a significant decrease in clonogenic ability of cancer cells treated with compound <ce:bold>7d</ce:bold> at 1–10 μM for 48 h. Therefore, compound <ce:bold>7d</ce:bold> dose-dependently inhibited the proliferation of STAT3 dependent MDA-MB-231 cells.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.8" view="all">
                     <ce:label>2.8</ce:label>
                     <ce:section-title id="sectitle0075">Compound <ce:bold>7d</ce:bold> arrested tumor growth <ce:italic>in vivo</ce:italic>
                     </ce:section-title>
                     <ce:para id="p0100" view="all">A mouse-xenograft model bearing inoculation of mice breast cancer 4T1 cells was used to evaluate the antitumor effect of compound <ce:bold>7d</ce:bold> 
                        <ce:italic>in vivo</ce:italic> 
                        <ce:cross-refs refid="bib38 bib39 bib40 bib41" id="crosrefs0075">[38–41]</ce:cross-refs>. Doxorubicin was used as a positive control. The data showed that compound <ce:bold>7d</ce:bold> (10 mg/kg, 20 mg/kg) significantly inhibited tumor growth as reflected in decreased tumor weight (<ce:cross-ref refid="fig6" id="crosref0160">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor>A). The inhibitory rates based on the tumor weight were markedly increased treated with compound <ce:bold>7d</ce:bold> (<ce:cross-ref refid="fig6" id="crosref0165">Fig. 6</ce:cross-ref>B). Notably, no obvious body weight loss of compound <ce:bold>7d</ce:bold> was observed even at 20 mg/kg, comparing to the acute body weight loss of the doxorubicin group (<ce:cross-ref refid="fig6" id="crosref0170">Fig. 6</ce:cross-ref>C). And the level of p-STAT3 (Y705) was also inhibited in tumor tissues from mice treated with compound <ce:bold>7d</ce:bold> (<ce:cross-ref refid="fig6" id="crosref0175">Fig. 6</ce:cross-ref>D). All these results demonstrated that compound <ce:bold>7d</ce:bold> is a potent and orally bioavailable anticancer drug candidate which is promising for further clinical development.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.9" view="all">
                     <ce:label>2.9</ce:label>
                     <ce:section-title id="sectitle0080">Molecular docking study</ce:section-title>
                     <ce:para id="p0105" view="all">All of our present efforts had been directed towards gaining better understanding on the effectiveness of the synthesized compounds and guiding further SAR studies. With the purpose of achieving this goal, we proceeded to detect the molecular docking of compound <ce:bold>7d</ce:bold> with STAT3 protein <ce:cross-refs refid="bib6 bib42" id="crosrefs0080">[6,42]</ce:cross-refs>. Docking experiments were operated using Autodock4.2. Compound <ce:bold>7d</ce:bold> was blindly docked to the crystal structure of STAT3 protein (PDB: <ce:inter-ref xlink:href="pdb:1BG1" id="intref0010" xlink:type="simple">1BG1</ce:inter-ref>). Through the analysis of the binding modes (<ce:cross-ref refid="fig7" id="crosref0180">Fig. 7</ce:cross-ref>
                        <ce:float-anchor refid="fig7"/></ce:float-anchor>), compound <ce:bold>7d</ce:bold> tightly bounds to STAT3 <ce:italic>via</ce:italic> four hydrogen bond (HB) interactions, including HB between the hydroxyl group of the caffeic acid moiety and the amine group of the LYS591 residue (distance O<ce:glyph name="sbnd"/></ce:glyph>N⋯H = 2.159 Å); HB between the oxygen atom of the amide linkage and the amine group of the GLN635 residue (distance O<ce:glyph name="sbnd"/></ce:glyph>N⋯H = 1.928 Å); HB between the nitrogen atom of the amide linker and the amide bond of the SER636 (distance <ce:italic>N</ce:italic>
                        <ce:glyph name="sbnd"/></ce:glyph>O⋯H = 1.985 Å); and HB between the hydroxyl group on A ring of RES and the amide bond of the ILE659 (distance O<ce:glyph name="sbnd"/></ce:glyph>N⋯H = 2.186 Å). Compound <ce:bold>7d</ce:bold> was predicted to interact with the SH2 domain of STAT3, thus inhibiting the dimerization and activation of STAT3.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0085">Conclusion</ce:section-title>
                  <ce:para id="p0110" view="all">In summary, two series of novel resveratrol-caffeic acid hybrids were designed, synthesized and evaluated as acetylated and phosphorylated STAT3 inhibitors. Particularly, the most potent compound <ce:bold>7d</ce:bold> exhibited remarkable antitumor activity against human breast cancer line MDA-MB-231 with an IC<ce:inf loc="post">50</ce:inf> value of 0.96 μM. Mechanism study suggested that compound <ce:bold>7d</ce:bold> inhibited acetyl-Lys685 and phospho-Tyr705 STAT3 in a dose-dependent manner, thereby affected the expressions of p-STAT3/Ac-STAT3 related genes. <ce:bold>7d</ce:bold> inhibited the colony formation of cancer cells while induced the apoptosis. Moreover, compound <ce:bold>7d</ce:bold> orally and significantly inhibited tumor growth <ce:italic>in vivo</ce:italic>, and exhibited better safety than doxorubicin. Molecular docking confirmed that compound <ce:bold>7d</ce:bold> tightly bound to the SH2 domain of STAT3 and further provided a rationale for SAR. In general, we demonstrated the novel idea that simultaneously inhibiting both acetylated and phosphorylated sites of the single STAT3 target was feasible and more efficient than targeting on either single site for cancer therapy, which was also the first report of the synthetic inhibitors simultaneously targeting on two biological reactions of STAT3 to our knowledge.</ce:para>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0090">Experimental section</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0095">Chemistry</ce:section-title>
                     <ce:para id="p0115" view="all">All common reagents and solvents were obtained from commercial suppliers and used without further purification. Reaction progress was monitored using analytical thin layer chromatography (TLC) on precoated silica gel GF254 plates (Qingdao Haiyang Chemical Plant, Qingdao, China) plates and the spots were detected under UV light (254 nm). Column chromatography was performed on silica gel (90–150 <ce:italic>μ</ce:italic>m; Qingdao Marine Chemical Inc.) The amount of silica gel used in column chromatography was 50–100 times the weight charged on the column. Melting point was measured on an XT-4 micromelting point instrument and uncorrected. All the <ce:sup loc="pre">1</ce:sup>H NMR and <ce:sup loc="pre">13</ce:sup>C NMR spectra were measured on a Bruker ACF-500 spectrometer at 25 °C and referenced to TMS. Chemical shifts are reported in ppm (<ce:italic>δ</ce:italic>) using the residual solvent line as internal standard. Splitting patterns were designed as s, singlet; br.s, broad single; d, doublet; t, triplet; m, multiplet. The purity of all compounds used for biological evaluation was confirmed to be higher than 95% through analytical HPLC performed with Agilent 1100 HPLC System. Mass spectra were obtained on a MS Agilent 1100 Series LC/MSD Trap mass spectrometer (ESI-MS) and a Mariner ESI-TOF spectrometer (HRESI-MS), respectively.</ce:para>
                     <ce:section id="sec4.1.1" view="all">
                        <ce:label>4.1.1</ce:label>
                        <ce:section-title id="sectitle0100">General procedures for the preparation of diethyl 4-nitrobenzylphosphonate (<ce:bold>2</ce:bold>)</ce:section-title>
                        <ce:para id="p0120" view="all">A mixture of 4-nitrobenzyl bromide (1, 10 mmol, 2.16 g) and triethyl phosphite (30 mmol, 4.98 g) was heated at reflux in an oil bath for 40 min. After the mixture was cooled, the excess triethyl phosphite was removed <ce:italic>in vacuo</ce:italic>. The intermediate <ce:bold>2</ce:bold> was further used without purification. Yield 89%, brown oil; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 8.19 (2H, d, <ce:italic>J</ce:italic> = 8.7 Hz), 7.58 (2H, dd, <ce:italic>J</ce:italic> = 8.7 Hz, 2.3 Hz), 4.07 (4H, q, <ce:italic>J</ce:italic> = 7.1 Hz), 3.48 (2H, d, <ce:italic>J</ce:italic> = 22.4 Hz), 1.19 (6H, t, <ce:italic>J</ce:italic> = 7.1 Hz); ESI-MS <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: 274.1 [M+H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.2" view="all">
                        <ce:label>4.1.2</ce:label>
                        <ce:section-title id="sectitle0105">General procedure for the preparation of (E)-1,3-dimethoxy-5-(4-nitro- styryl)benzene (<ce:bold>4</ce:bold>)</ce:section-title>
                        <ce:para id="p0125" view="all">The solution of intermediate <ce:bold>2</ce:bold> in 15 mL of dry dimethyl formamide was stirred and then sodium methoxide (60 mmol, 3.24 g) was added, which was stirred at 0 °C for 30 min, and the 3,5-dimethoxybenzaldehyde (<ce:bold>3</ce:bold>, 12 mmol, 1.99 g) dissolved in 10 mL of dimethyl formamide was added dropwise at 0 °C. The mixture was stirred at room temperature overnight. The reaction was quenched by pouring into 200 mL of ice water. After stewing for 10–20 min, the solid precipitated was collected by filtration, washed with water and petroleum ether and then recrystallized from ethanol. Yield 76%, yellow solid; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 8.20 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 7.61 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 7.18 (d, <ce:italic>J</ce:italic> = 16.2 Hz, 1H), 7.09 (d, <ce:italic>J</ce:italic> = 16.2 Hz, 1H), 6.68 (d, <ce:italic>J</ce:italic> = 1.8 Hz, 2H), 6.43 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 3.83 (s, 6H); ESI-MS <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: 286.1 [M+H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.3" view="all">
                        <ce:label>4.1.3</ce:label>
                        <ce:section-title id="sectitle0110">General procedure for the preparation of (E)-4-(3,5-dimethoxystyryl)aniline (<ce:bold>5</ce:bold>)</ce:section-title>
                        <ce:para id="p0130" view="all">Compound <ce:bold>4</ce:bold> (7 mmol, 2.00 g) dissolved in ethyl acetate (15 mL) was added with tin (II) chloride dihydrate (35 mmol, 7.90 g) and the mixture was refluxed for 5 h. The reaction was then terminated by the addition of saturated sodium bicarbonate solution. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with water and brine and then dried over anhydrous magnesium sulfate. The solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography to give the target compound. Yield 89%, pale yellow solid; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.33 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 7.00 (d, <ce:italic>J</ce:italic> = 16.2 Hz, 1H), 6.85 (d, <ce:italic>J</ce:italic> = 16.2 Hz, 1H), 6.67 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 6.64 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 2H), 6.36 (t, <ce:italic>J</ce:italic> = 2.1 Hz,1H), 6.36 (s, 6H), 3.75 (br.s, 2H); ESI-MS <ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>: 256.1 [M+H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.4" view="all">
                        <ce:label>4.1.4</ce:label>
                        <ce:section-title id="sectitle0115">General procedure for the preparation of compounds <ce:bold>7a-7o</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0135" view="all">A solution of the appropriate caffic acid derivitives (1 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo [4,5-b]pyridinium 3-oxid hexafl-uorophosphate (HATU) (1.2 mmol) and <ce:italic>N,N</ce:italic>-diisopropylethylamine (2 mmol) in dichloromethane was stirred at ambient temperature for 30 min. Compound <ce:bold>4</ce:bold> (1 mmol) was added to the solution, and stirred overnight. The reaction mixture was diluted with water and extracted with dichloromethane. The organic layer was washed with diluted hydrochloric acid, saturated sodium bicarbonate solution and brine. And dried with anhydrous magnesium sulfate, and the solvent was evaporated in vacuum to give the crude product, which was purified by chromatography on silica gel.</ce:para>
                        <ce:section id="sec4.1.4.1" view="all">
                           <ce:label>4.1.4.1</ce:label>
                           <ce:section-title id="sectitle0120">
                              <ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)cinnamamide (<ce:bold>7a</ce:bold>)</ce:section-title>
                           <ce:para id="p0140" view="all">Yield 91%, white solid, m.p. 209–211 °C; IR (KBr) <ce:italic>ν</ce:italic> 3328, 1661, 1589, 1532, 1340, 1151, 1067, 844, 765 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 10.30 (s, 1H), 7.73 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.65–7.61 (m, 3H), 7.57 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 2H), 7.44 (dt, <ce:italic>J</ce:italic> = 21.0, 7.0 Hz, 3H), 7.23 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.10 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 6.85 (d, <ce:italic>J</ce:italic> = 15.7 Hz, 1H), 6.76 (d, <ce:italic>J</ce:italic> = 1.9 Hz, 2H), 6.40 (t, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 3.78 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 163.43, 160.64, 140.18, 139.24, 138.79, 134.68, 132.09, 129.72, 128.95, 128.51, 127.66, 127.15, 127.01, 122.19, 119.32, 104.32, 99.69, 55.16; HRMS (ESI) <ce:italic>m/z</ce:italic> 384.1603 [M − H]<ce:sup loc="post">-</ce:sup> (calcd for 384.1605, C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">22</ce:inf>NO<ce:inf loc="post">3</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.2" view="all">
                           <ce:label>4.1.4.2</ce:label>
                           <ce:section-title id="sectitle0125">(E)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)-3-(4-methoxyphenyl)acrylamide (<ce:bold>7b</ce:bold>)</ce:section-title>
                           <ce:para id="p0145" view="all">Yield 87%, white solid, m.p. 204–207 °C; IR (KBr) <ce:italic>ν</ce:italic> 3353, 1661, 1588, 1512, 1252, 1155, 1069, 825 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 10.19 (s, 1H), 7.71 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.60–7.52 (m, 5H), 7.22 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.09 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.02 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 6.76 (d, <ce:italic>J</ce:italic> = 1.8 Hz, 2H), 6.69 (d, <ce:italic>J</ce:italic> = 15.6 Hz, 1H), 6.40 (t, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 3.81 (s, 3H), 3.78 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 163.75, 160.63, 139.94, 139.25, 129.84, 129.31, 128.54, 126.99, 119.60, 119.22, 114.45, 114.30, 104.28, 99.66, 55.26, 55.15; HRMS (ESI) <ce:italic>m/z</ce:italic> 438.1671 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 438.1676, C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">25</ce:inf>NNaO<ce:inf loc="post">4</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.3" view="all">
                           <ce:label>4.1.4.3</ce:label>
                           <ce:section-title id="sectitle0130">(E)-3-(3,4-dimethoxyphenyl)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)acrylamide (<ce:bold>7c</ce:bold>)</ce:section-title>
                           <ce:para id="p0150" view="all">Yield 83%, white solid, m.p. 167–169 °C; IR (KBr) <ce:italic>ν</ce:italic> 3438, 1591, 1515, 1338, 1258, 1156, 1066, 964, 846 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 10.21 (s, 1H), 7.73 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 2H), 7.57 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 2H), 7.54 (d, <ce:italic>J</ce:italic> = 15.2 Hz, 1H), 7.22 (dd, <ce:italic>J</ce:italic> = 17.2, 10.6 Hz, 3H), 7.09 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.02 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H), 6.76 (s, 2H), 6.72 (d, <ce:italic>J</ce:italic> = 15.6 Hz, 1H), 6.41 (t, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 3.83 (s, 3H), 3.81 (s, 3H), 3.78 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 163.78, 160.65, 150.45, 148.97, 140.33, 139.28, 139.01, 131.92, 128.57, 127.50, 127.02, 121.75, 119.80, 119.22, 111.85, 110.17, 104.31, 99.68, 55.58, 55.45, 55.17; HRMS (ESI) <ce:italic>m/z</ce:italic> 468.1783 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 468.1781, C<ce:inf loc="post">227</ce:inf>H<ce:inf loc="post">27</ce:inf>NNaO<ce:inf loc="post">5</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.4" view="all">
                           <ce:label>4.1.4.4</ce:label>
                           <ce:section-title id="sectitle0135">(E)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)-3-(3,4,5-trimethoxyphenyl)acrylamide (<ce:bold>7d</ce:bold>)</ce:section-title>
                           <ce:para id="p0155" view="all">Yield 89%, yellow solid, m.p. 80–83 °C; IR (KBr) <ce:italic>ν</ce:italic> 3447, 2935, 1588, 1504, 1327, 1151, 1125, 824 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.67 (d, <ce:italic>J</ce:italic> = 15.4 Hz, 1H), 7.62 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.50 (t, <ce:italic>J</ce:italic> = 9.0 Hz, 3H), 7.05 (d, <ce:italic>J</ce:italic> = 16.2 Hz, 1H), 6.98 (d, <ce:italic>J</ce:italic> = 16.2 Hz, 1H), 6.76 (s, 2H), 6.66 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 2H), 6.48 (d, <ce:italic>J</ce:italic> = 15.4 Hz, 1H), 6.40 (s, 1H), 3.89 (s, 3H), 3.88 (s, 6H), 3.83 (s, 9H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic>163.88, 160.65, 150.45, 148.97, 140.33, 139.28, 139.01, 131.92, 128.57, 127.50, 127.02, 121.75, 119.80, 119.22, 111.85, 110.17, 104.31, 99.68, 55.59, 55.45, 55.15; HRMS (ESI) <ce:italic>m/z</ce:italic> 476.2071 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 476.2068, C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">30</ce:inf>NO<ce:inf loc="post">6</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.5" view="all">
                           <ce:label>4.1.4.5</ce:label>
                           <ce:section-title id="sectitle0140">(E)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)-3-(4-hydroxy-3,5-dimethoxyphenyl)ac-rylamide (<ce:bold>7e</ce:bold>)</ce:section-title>
                           <ce:para id="p0160" view="all">Yield 78%, brown solid, m.p. 87–89 °C; IR (KBr) <ce:italic>ν</ce:italic> 3399, 1592, 1512, 1328, 1152, 1113, 826 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 10.18 (s, 1H), 8.89 (s, 1H), 7.72 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.56 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.51 (d, <ce:italic>J</ce:italic> = 15.5 Hz, 1H), 7.23 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.23 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 6.93 (s, 2H), 6.76 (d, <ce:italic>J</ce:italic> = 1.9 Hz, 2H), 6.68 (d, <ce:italic>J</ce:italic> = 15.6 Hz, 1H), 6.40 (t, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 3.82 (s, 6H), 3.78 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 163.81, 160.61, 160.28, 148.07, 145.08, 139.25, 139.05, 131.80, 128.55, 126.97, 125.01, 119.12, 105.51, 104.26, 103.98, 99.43, 98.47, 62.79, 55.96, 55.15, 54.99; HRMS (ESI) <ce:italic>m/z</ce:italic> 462.1913 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 462.1911, C<ce:inf loc="post">27</ce:inf>H<ce:inf loc="post">28</ce:inf>NO<ce:inf loc="post">6</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.6" view="all">
                           <ce:label>4.1.4.6</ce:label>
                           <ce:section-title id="sectitle0145">(E)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)-3-(4-(trifluoromethyl)phenyl)acrylami-de (<ce:bold>7f</ce:bold>)</ce:section-title>
                           <ce:para id="p0165" view="all">Yield 91%, pale yellow solid, m.p. 189–191 °C; IR (KBr) <ce:italic>ν</ce:italic> 3320, 1593, 1524, 1325, 1127, 1068, 830 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 10.39 (s, 1H), 7.86 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 2H), 7.82 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 7.73 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.67 (d, <ce:italic>J</ce:italic> = 15.7 Hz, 1H), 7.59 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.24 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.11 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 6.97 (d, <ce:italic>J</ce:italic> = 15.7 Hz, 1H), 6.77 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 2H), 6.41 (t, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 3.78 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 162.92, 160.62, 139.20, 138.60, 138.38, 132.28, 128.46, 128.28, 127.25, 127.03, 125.80, 125.03, 119.37, 104.31, 99.69, 55.16; HRMS (ESI) <ce:italic>m/z</ce:italic> 454.1621 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 454.1625, C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">23</ce:inf>F<ce:inf loc="post">3</ce:inf>NO<ce:inf loc="post">3</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.7" view="all">
                           <ce:label>4.1.4.7</ce:label>
                           <ce:section-title id="sectitle0150">(E)-3-(4-cyanophenyl)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)acrylamide (<ce:bold>7g</ce:bold>)</ce:section-title>
                           <ce:para id="p0170" view="all">Yield 88%, yellow solid, m.p. 179–182 °C; IR (KBr) <ce:italic>ν</ce:italic> 3424, 2924, 1591, 1532, 1208, 1153, 1067, 957, 824 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 10.40 (s, 1H), 7.91 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 2H), 7.82 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 2H), 7.72 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.65 (d, <ce:italic>J</ce:italic> = 15.7 Hz, 1H), 7.58 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.23 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.11 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 6.97 (d, <ce:italic>J</ce:italic> = 15.7 Hz, 1H), 6.76 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 2H), 6.41 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 3.78 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 162.48, 160.65, 139.33, 139.22, 138.56, 138.26, 132.83, 132.35, 128.47, 128.35, 127.30, 127.05, 125.70, 119.42, 111.64, 104.34, 99.72, 55.17; HRMS (ESI) <ce:italic>m/z</ce:italic> 433.1519 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 433.1523, C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">22</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">3</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.8" view="all">
                           <ce:label>4.1.4.8</ce:label>
                           <ce:section-title id="sectitle0155">(E)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)-3-(4-nitrophenyl)acrylamide (<ce:bold>7h</ce:bold>)</ce:section-title>
                           <ce:para id="p0175" view="all">Yield 90%, yellow solid, m.p. 226–228 °C; IR (KBr) <ce:italic>ν</ce:italic> 3446, 3071, 1704, 1625, 1517, 1493, 1344, 1100, 977, 843, 766 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 10.44 (s, 1H), 8.30 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 7.90 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 7.73 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.71 (d, <ce:italic>J</ce:italic> = 15.7 Hz, 1H), 7.59 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.24 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.11 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.02 (d, <ce:italic>J</ce:italic> = 15.8 Hz, 1H), 6.76 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 2H), 6.41 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 3.78 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 162.71, 160.64, 151.04, 147.65, 141.26, 139.20, 138.51, 137.69, 128.76, 128.70, 128.46, 127.32, 127.05, 124.10, 119.42, 104.34, 55.16; HRMS (ESI) <ce:italic>m/z</ce:italic> 431.1559 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 436.1601, C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">23</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">5</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.9" view="all">
                           <ce:label>4.1.4.9</ce:label>
                           <ce:section-title id="sectitle0160">(E)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)-3-(4-fluorophenyl)acrylamide(<ce:bold>7i</ce:bold>)</ce:section-title>
                           <ce:para id="p0180" view="all">Yield 86%, white solid, m.p. 221–223 °C; IR (KBr) <ce:italic>ν</ce:italic> 3323, 1663, 1589, 1459, 1340, 1155, 832 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 10.28 (s, 1H), 7.74–7.68 (m, 4H), 7.60 (d, <ce:italic>J</ce:italic> = 17.6 Hz, 2H), 7.57 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.29 (t, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.23 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.10 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 6.79 (d, <ce:italic>J</ce:italic> = 14.6 Hz, 1H), 6.76 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 2H), 6.41 (t, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 3.78 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 163.34, 161.83, 160.62, 139.22, 138.94, 129.88, 129.81, 128.49, 127.13, 127.00, 119.31, 116.02, 115.85, 104.30, 99.67, 55.15; HRMS (ESI) <ce:italic>m/z</ce:italic> 404.1653 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 404.1656, C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">23</ce:inf>FNO<ce:inf loc="post">3</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.10" view="all">
                           <ce:label>4.1.4.10</ce:label>
                           <ce:section-title id="sectitle0165">(E)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)-3-(3-fluorophenyl)acrylamide(<ce:bold>7j</ce:bold>)</ce:section-title>
                           <ce:para id="p0185" view="all">Yield 81%, white solid, m.p. 144–147 °C; IR (KBr) <ce:italic>ν</ce:italic> 3322, 1589, 1531, 1454, 1153, 983, 845 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 10.33 (s,1H), 7.72 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.60 (d, <ce:italic>J</ce:italic> = 14.8 Hz, 2H), 7.58 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 2H), 7.51–7.46 (m, 2H), 7.24 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 2H), 7.10 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 6.88 (d, <ce:italic>J</ce:italic> = 15.7 Hz, 1H), 6.76 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 2H), 6.41 (t, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 3.78 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 163.09, 161.43, 160.61, 139.20, 138.78, 138.65, 132.18, 128.47, 127.19, 127.00, 123.79, 119.34, 104.30, 99.69, 55.15; HRMS (ESI) <ce:italic>m/z</ce:italic> 426.1477 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 426.1476, C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">22</ce:inf>FNNaO<ce:inf loc="post">3</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.11" view="all">
                           <ce:label>4.1.4.11</ce:label>
                           <ce:section-title id="sectitle0170">(E)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)-3-(2-fluorophenyl)acrylamide(<ce:bold>7k</ce:bold>)</ce:section-title>
                           <ce:para id="p0190" view="all">Yield 83%, white solid, m.p. 187–190 °C; IR (KBr) <ce:italic>ν</ce:italic> 3434, 1595, 1536, 1350, 1152, 839, 754 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 10.41 (s, 1H), 7.89 (d, <ce:italic>J</ce:italic> = 15.6 Hz, 1H), 7.78 (dd, <ce:italic>J</ce:italic> = 6.1, 3.3 Hz, 1H), 7.73 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.61–7.54 (m, 3H), 7.47–7.43 (m, 2H), 7.24 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.11 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 6.91 (d, <ce:italic>J</ce:italic> = 15.6 Hz, 1H), 6.76 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 2H), 6.41 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 3.78 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 162.89, 160.62, 135.33, 133.38, 131.12, 130.01, 128.46, 127.78, 127.66, 127.27, 127.02, 125.29, 119.39, 104.32, 99.70, 55.15; HRMS (ESI) <ce:italic>m/z</ce:italic> 426.1478 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 426.1476, C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">22</ce:inf>FNNaO<ce:inf loc="post">3</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.12" view="all">
                           <ce:label>4.1.4.12</ce:label>
                           <ce:section-title id="sectitle0175">(E)-3-(2,4-difluorophenyl)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)acrylamide (<ce:bold>7l</ce:bold>)</ce:section-title>
                           <ce:para id="p0195" view="all">Yield 78%, yellow solid, m.p. 196–198 °C; IR (KBr) <ce:italic>ν</ce:italic> 3315, 1667, 1591, 1530, 1208, 1153, 1061, 966, 872, 831 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 10.38 (s,1H), 7.79 (dd, <ce:italic>J</ce:italic> = 15.4, 8.6 Hz, 1H), 7.73 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.60 (d, <ce:italic>J</ce:italic> = 16.6 Hz, 2H), 7.58 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 2H), 7.42–7.35 (m, 1H), 7.23 (d, <ce:italic>J</ce:italic> = 16.6 Hz, 2H), 7.10 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 6.91 (d, <ce:italic>J</ce:italic> = 15.9 Hz, 1H), 6.76 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 2H), 6.41 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 3.78 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 163.13, 160.63, 139.22, 138.67, 132.22, 131.87, 128.48, 127.22, 127.02, 119.37, 112.51, 112.37, 104.70, 104.31, 99.69, 55.15; HRMS (ESI) <ce:italic>m/z</ce:italic> 444.1378 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 444.1382, C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">21</ce:inf>F<ce:inf loc="post">2</ce:inf>NNaO<ce:inf loc="post">3</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.13" view="all">
                           <ce:label>4.1.4.13</ce:label>
                           <ce:section-title id="sectitle0180">(E)-3-(4-chlorophenyl)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)acrylamide (<ce:bold>7m</ce:bold>)</ce:section-title>
                           <ce:para id="p0200" view="all">Yield 86%, white solid, m.p. 202–205 °C; IR (KBr) <ce:italic>ν</ce:italic> 3434, 1659, 1589, 1535, 1202, 1154, 1066, 828 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 10.33 (s, 1H), 7.74 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 7.68 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H), 7.60 (dd, <ce:italic>J</ce:italic> = 12.0, 8.3 Hz, 3H), 7.54 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 2H), 7.25 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.12 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 6.87 (d, <ce:italic>J</ce:italic> = 15.7 Hz, 1H), 6.78 (d, <ce:italic>J</ce:italic> = 1.8 Hz, 2H), 6.41 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 3.80 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 163.31, 160.63, 139.22, 138.87, 132.22, 131.91, 129.48, 127.19, 127.02, 119.37, 115.51, 104.86, 104.31, 99.68, 55.16; HRMS (ESI) <ce:italic>m/z</ce:italic> 442.1181 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 442.1180, C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">22</ce:inf>ClNNaO<ce:inf loc="post">3</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.14" view="all">
                           <ce:label>4.1.4.14</ce:label>
                           <ce:section-title id="sectitle0185">(E)-3-(4-bromophenyl)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)acrylamide (<ce:bold>7n</ce:bold>)</ce:section-title>
                           <ce:para id="p0205" view="all">Yield 80%, white solid, m.p. 221–224 °C; IR (KBr) <ce:italic>ν</ce:italic> 3435, 1659, 1589, 1155, 1069, 822 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 10.31 (s, 1H), 7.72 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.66 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.57 (dd, <ce:italic>J</ce:italic> = 15.1, 6.4 Hz, 5H), 7.23 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.10 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 6.86 (d, <ce:italic>J</ce:italic> = 15.7 Hz, 1H), 6.76 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 2H), 6.40 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 3.78 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 163.22, 160.64, 138.87, 132.17, 131.94, 129.59, 128.50, 127.19, 127.02, 119.34, 104.32, 104.31, 99.68, 55.16; HRMS (ESI) <ce:italic>m/z</ce:italic> 464.0860 [7 M + H]<ce:sup loc="post">+</ce:sup> (calcd for 464.0856, C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">23</ce:inf>BrNO<ce:inf loc="post">3</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.15" view="all">
                           <ce:label>4.1.4.15</ce:label>
                           <ce:section-title id="sectitle0190">(E)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)-3-(pyridin-2-yl)acrylamide (<ce:bold>7o</ce:bold>)</ce:section-title>
                           <ce:para id="p0210" view="all">Yield 77%, yellow solid, m.p. 137–140 °C; IR (KBr) <ce:italic>ν</ce:italic> 3333, 2990, 2833, 1587, 1584, 1342, 1200, 1145, 1063, 964, 827 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 10.45 (s, 1H), 8.65 (d, <ce:italic>J</ce:italic> = 4.3 Hz, 1H), 7.87 (td, <ce:italic>J</ce:italic> = 7.7, 1.3 Hz, 1H), 7.74 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.64 (d, <ce:italic>J</ce:italic> = 9.3 Hz, 1H), 7.61–7.55 (m, 3H), 7.39 (dd, <ce:italic>J</ce:italic> = 7.3, 4.9 Hz, 1H), 7.34 (d, <ce:italic>J</ce:italic> = 15.3 Hz, 1H), 7.23 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.11 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 6.76 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 2H), 6.41 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 3.78 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 183.21, 160.64, 152.76, 149.85, 139.37,139.23, 138.72, 137.19, 132.22, 128.51, 127.21, 127.01, 125.84, 124.53, 124.20, 119.35, 104.31, 99.71, 55.15; HRMS (ESI) <ce:italic>m/z</ce:italic> 409.1526 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 409.1523, C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">22</ce:inf>N<ce:inf loc="post">2</ce:inf>NaO<ce:inf loc="post">3</ce:inf>).</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.5" view="all">
                        <ce:label>4.1.5</ce:label>
                        <ce:section-title id="sectitle0195">Procedure for the preparation of compound <ce:bold>10p</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0215" view="all">To a mixture of caffeic acid (<ce:bold>6p</ce:bold>, 1 mmol) and pyridine (1 mmol) was added acetic anhydride (5 mmol) and stirred at room temperature until the reaction was completed. The reaction mixture was then diluted with dichloromethane (5 mL) and washed with diluted hydrochloric acid and brine. The organic layer was then dried over magnesium sulfate and concentrated to dryness to afford intermediate <ce:bold>8p</ce:bold>. Then <ce:bold>8p</ce:bold> was reacted with compound <ce:bold>5</ce:bold> to give compound <ce:bold>9p</ce:bold>. Compound <ce:bold>9p</ce:bold> was refluxed with the sulfuric acid solution diluted in ethanol for 2 h. Finally, targeted product <ce:bold>10p</ce:bold> was acquired.</ce:para>
                        <ce:section id="sec4.1.5.1" view="all">
                           <ce:label>4.1.5.1</ce:label>
                           <ce:section-title id="sectitle0200">(E)-3-(3,4-dihydroxyphenyl)-<ce:italic>N</ce:italic>-(4-(3,5-dimethoxystyryl)phenyl)acrylamide (<ce:bold>10p</ce:bold>)</ce:section-title>
                           <ce:para id="p0220" view="all">42%, pale yellow solid, m.p. 203–205 °C; IR (KBr) <ce:italic>ν</ce:italic> 3299, 1597, 1534, 1272, 1204, 1149, 826 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 10.16 (s, 1H), 9.39 (br.s, 2H), 7.71 (d, <ce:italic>J</ce:italic> = 7.1 Hz, 2H), 7.55 (d, <ce:italic>J</ce:italic> = 7.2 Hz, 2H), 7.41 (d, <ce:italic>J</ce:italic> = 15.6 Hz, 1H), 7.22 (d, <ce:italic>J</ce:italic> = 16.5 Hz, 1H), 7.09 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.02 (s, 1H), 6.92 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H), 6.77 (d, <ce:italic>J</ce:italic> = 14.8 Hz, 3H), 6.55 (d, <ce:italic>J</ce:italic> = 15.7 Hz, 1H), 6.40 (d, <ce:italic>J</ce:italic> = 1.8 Hz, 1H), 3.78 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 163.94, 160.62, 145.57, 140.79, 139.26, 131.77, 128.55, 126.95, 120.74, 119.17, 118.29, 115.77, 113.97, 104.27, 99.65, 79.15, 79.09, 78.88, 78.62, 55.14; HRMS (ESI) <ce:italic>m/z</ce:italic> 440.1469 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 440.1468, C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">23</ce:inf>NNaO<ce:inf loc="post">5</ce:inf>).</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.6" view="all">
                        <ce:label>4.1.6</ce:label>
                        <ce:section-title id="sectitle0205">General procedure for the preparation of compounds <ce:bold>12a</ce:bold>-<ce:bold>12i</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0225" view="all">The caffic acid derivitives (1 mmol), HATU (1.2 mmol) and <ce:italic>N</ce:italic>,<ce:italic>N</ce:italic>-diisopropylethylamine (2 mmol) were dissolved in dichloromethane and stirred at room temperature for 30 min. Compound <ce:bold>11</ce:bold> (1 mmol) was then added to the solution, and stirred overnight. The reaction mixture was extracted with dichloromethane. The organic layer was washed with diluted hydrochloric acid, saturated sodium bicarbonate solution and brine. Then it was dried with anhydrous magnesium sulfate, and the solvent was evaporated in vacuum to give the crude product, which was purified by chromatography on silica gel.</ce:para>
                        <ce:section id="sec4.1.6.1" view="all">
                           <ce:label>4.1.6.1</ce:label>
                           <ce:section-title id="sectitle0210">4-(3,5-dimethoxystyryl)phenyl cinnamate (<ce:bold>12a</ce:bold>)</ce:section-title>
                           <ce:para id="p0230" view="all">Yield 93%, white solid, m.p. 138–139 °C; IR (KBr) <ce:italic>ν</ce:italic> 3432, 1731, 1633, 1594, 1311, 1145, 840 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 7.88 (d, <ce:italic>J</ce:italic> = 16.0 Hz, 1H), 7.85–7.79 (m, 2H), 7.67 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.50–7.45 (m, 3H), 7.31 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.23 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.18 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 6.90 (d, <ce:italic>J</ce:italic> = 16.0 Hz, 1H), 6.79 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 2H), 6.43 (t, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 3.79 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 164.84, 160.66, 149.91, 146.45, 138.98, 134.68, 133.82, 128.96, 128.60, 127.97, 127.46, 122.04, 117.14, 104.52, 99.95, 55.19; HRMS (ESI) <ce:italic>m/z</ce:italic> 387.1587 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 387.1591, C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">23</ce:inf>O<ce:inf loc="post">4</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.2" view="all">
                           <ce:label>4.1.6.2</ce:label>
                           <ce:section-title id="sectitle0215">(E)-4-(3,5-dimethoxystyryl)phenyl 3-(3,4,5-trimethoxyphenyl)acrylate (<ce:bold>12d</ce:bold>)</ce:section-title>
                           <ce:para id="p0235" view="all">Yield 87%, white solid, m.p. 157–159 °C; IR (KBr) <ce:italic>ν</ce:italic> 3438, 1720, 1586, 1503, 1422, 1247, 1194, 1124, 840 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 7.81 (d, <ce:italic>J</ce:italic> = 15.9 Hz, 1H), 7.67 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.31 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.23 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.20–7.14 (m, 3H), 6.92 (d, <ce:italic>J</ce:italic> = 15.9 Hz, 1H), 6.79 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 2H), 6.43 (t, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 3.84 (s, 6H), 3.79 (s, 6H), 3.72 (s, 3H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 163.51, 160.64, 153.09, 140.35, 139.25, 138.90, 132.01, 130.24, 128.54, 127.09, 127.01, 121.45, 119.24, 105.23, 104.30, 99.69, 60.08, 55.90, 55.16; HRMS (ESI) <ce:italic>m/z</ce:italic> 477.1913 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 477.1908, C<ce:inf loc="post">28</ce:inf>H<ce:inf loc="post">29</ce:inf>O<ce:inf loc="post">7</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.3" view="all">
                           <ce:label>4.1.6.3</ce:label>
                           <ce:section-title id="sectitle0220">(E)-4-(3,5-dimethoxystyryl)phenyl 3-(4-(trifluoromethyl)phenyl)acrylate (<ce:bold>12f</ce:bold>)</ce:section-title>
                           <ce:para id="p0240" view="all">Yield 84%, white solid, m.p. 142–145 °C; IR (KBr) <ce:italic>ν</ce:italic> 3436, 1732, 1594, 1317, 1149, 1125, 1065, 836 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 8.08 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 7.98 (d, <ce:italic>J</ce:italic> = 16.1 Hz, 1H), 7.85 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 2H), 7.70 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.34 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.27 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H), 7.21 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.08 (d, <ce:italic>J</ce:italic> = 16.1 Hz, 1H), 6.82 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 2H), 6.45 (t, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 3.81 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 164.47, 160.64, 149.79, 144.48, 138.95, 137.80, 134.78, 129.20, 128.70, 127.91, 127.47, 125.73, 125.70, 121.97, 120.09, 104.51, 99.94, 55.17; HRMS (ESI) <ce:italic>m/z</ce:italic> 455.1467 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 455.1465, C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">22</ce:inf>F<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">4</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.4" view="all">
                           <ce:label>4.1.6.4</ce:label>
                           <ce:section-title id="sectitle0225">(E)-4-(3,5-dimethoxystyryl)phenyl 3-(4-nitrophenyl)acrylate (<ce:bold>12h</ce:bold>)</ce:section-title>
                           <ce:para id="p0245" view="all">Yield 80%, yellow solid, m.p. 172–175 °C; IR (KBr) <ce:italic>ν</ce:italic> 3442, 1732, 1597, 1517, 1345, 1147, 842 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 8.31 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H), 8.13 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H), 8.02 (d, <ce:italic>J</ce:italic> = 16.1 Hz, 1H), 7.70 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.34 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.27 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H), 7.21 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.14 (d, <ce:italic>J</ce:italic> = 16.1 Hz, 1H), 6.82 (d, <ce:italic>J</ce:italic> = 2.1 Hz, 2H), 6.45 (t, <ce:italic>J</ce:italic> = 2.1 Hz, 1H), 3.81 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 164.31, 160.64, 148.29, 143.68, 140.17, 138.94, 129.67, 128.73, 127.90, 127.48, 123.92, 121.95, 121.48, 104.52, 99.95, 55.18; HRMS (ESI) <ce:italic>m/z</ce:italic> 432.1443 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 432.1442, C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">22</ce:inf>NO<ce:inf loc="post">6</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.6.5" view="all">
                           <ce:label>4.1.6.5</ce:label>
                           <ce:section-title id="sectitle0230">(E)-4-(3,5-dimethoxystyryl)phenyl 3-(4-fluorophenyl)acrylate (<ce:bold>12i</ce:bold>)</ce:section-title>
                           <ce:para id="p0250" view="all">Yield 82%, white solid, m.p. 115–117 °C; IR (KBr) <ce:italic>ν</ce:italic> 3444, 1732, 1593, 1242, 1150, 842, 674 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 7.88 (d, <ce:italic>J</ce:italic> = 16.0 Hz, 1H), 7.76 (d, <ce:italic>J</ce:italic> = 10.0 Hz, 1H), 7.67 (dd, <ce:italic>J</ce:italic> = 7.8, 3.5 Hz, 3H), 7.51 (dd, <ce:italic>J</ce:italic> = 14.2, 7.8 Hz, 1H), 7.31 (dd, <ce:italic>J</ce:italic> = 9.4, 7.2 Hz, 2H), 7.31 (dd, <ce:italic>J</ce:italic> = 9.4, 7.2 Hz, 2H), 7.19 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 6.99 (d, <ce:italic>J</ce:italic> = 16.1 Hz, 1H), 6.79 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 2H), 6.43 (t, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 3.79 (s, 6H); <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 164.61, 163.35, 161.41, 160.63, 144.98, 138.95, 134.72, 130.91, 129.67, 128.66, 127.92, 127.45, 125.06, 121.98, 118.78, 114.78, 104,51, 99.94, 55.17; HRMS (ESI) <ce:italic>m/z</ce:italic> 427.1315 [M+Na]<ce:sup loc="post">+</ce:sup> (calcd for 427.1316, C<ce:inf loc="post">25</ce:inf>H<ce:inf loc="post">21</ce:inf>FNaO<ce:inf loc="post">4</ce:inf>).</ce:para>
                        </ce:section>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0235">Cell line and cell culture</ce:section-title>
                     <ce:para id="p0255" view="all">Cancer cell line human colonic carcinoma HT29 and human breast cancer MDA-MB-231 were purchased from the Cell Bank of Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). Human coloniac carcinoma HT29 cells were cultured in RPMI 1640 medium plus 10% (vol/vol) fetal bovine serum (FBS), MDA-MB-231 cells were cultured in Dulbecco modified Eagle medium (DMEM), supplemented with 10% (vol/vol) of FBS, 50 μg/ml penicillin and 50 μg/ml streptomycin. Both cell lines were incubated at 37 °C in a humidified atmosphere containing 5% CO<ce:inf loc="post">2</ce:inf>.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.3" view="all">
                     <ce:label>4.3</ce:label>
                     <ce:section-title id="sectitle0240">MTT assay</ce:section-title>
                     <ce:para id="p0260" view="all">Cell viability of HT29 and MDA-MB-231 cells were measured by MTT assay. Cancer cells (HT29, MDA-MB-231) were seeded in 96-well culture plates (4–6 × 10<ce:sup loc="post">3</ce:sup> cells/well). After overnight incubation, the cells were treated with different concentrations of test compounds for 48 h. MTT (5 mg/mL) was dissolved in PBS and filter sterilized, then 20 μL of the prepared MTT solution was added to each well and the cells were incubated for another 4 h until a purple precipitate was visible. The formed formazan crystals were dissolved in dimethylsulfoxide (150 μL/well) by continuous shaking for 10 min. The absorbance was measured on an ELISA reader (Spectra Max Plus384, Molecular Devices, Sunnyvale, CA) at a test wavelength of 570 nm and a reference wavelength of 630 nm. The assays were performed at least three times in a parallel manner, for each compound seven concentrations were evaluated and each were done in three replicate wells.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.4" view="all">
                     <ce:label>4.4</ce:label>
                     <ce:section-title id="sectitle0245">Western blot assay</ce:section-title>
                     <ce:para id="p0265" view="all">Protein levels were determined by standard western blot. MDA-MB-231 cells were incubated with different concentrations of compound <ce:bold>7d</ce:bold> or 0.1% DMSO for 48 h. Harvested with trypsin, cells were treated with 1 × RIPA lysis buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40,1 mM EDTA and protease inhibitors PMSF) (Amresco, Solon, USA) to extract the total proteins. Then an aliquot of proteins from the total cell lysates (4–40 μg/lane) were separated by sodium dodecyl sulfate (8%, 10% or 12%) polyacrylamide gel electrophoresis (SDS–PAGE, BioRad Laboratories, Hercules, CA), wet-transferred to PVDF membrane (BioRad Laboratories, Hercules, CA) and blotted with primary antibodies specific for STAT1, p-STAT1, STAT3, p-STAT3, Ac-STAT3, <ce:italic>p</ce:italic>-Src, Erk, <ce:italic>p</ce:italic>-Erk, Bcl-2, Cyclin D1, Cleaved Casepase-3 and GAPDH as the internal standard overnight, and then were probed with secondary isotype specific antibodies for another 1 h at 37 °C. Bound immuno-complexes were detected using ChemiDOC™ XRS + system (BioRad Laboratories, Hercules, CA).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.5" view="all">
                     <ce:label>4.5</ce:label>
                     <ce:section-title id="sectitle0250">Quantitative real-time RT-PCR</ce:section-title>
                     <ce:para id="p0270" view="all">Levels of mRNA expression were analyzed with the RT-PCR assay, with total RNA isolated from MDA-MB-231 cells by using an EASYspin Plus tissue/cell RNA extraction kit (Aidlab Biotechnologies Co. Ltd). RNA was quantified by measuring absorption at 260 nm and 1 μg RNA was reverse transcribed to cDNA by using the Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics, Basel, Switzerland). Thermal cycling conditions included 95 °C initial denaturation for 5 min, followed by 40 cycles of denaturation (10 s at 95 °C), annealing (15 s at 60 °C) and extension (15 s at 72 °C with a single fluorescence measurement), a melt curve program (60–95 °C with a 0.11 °C/s heat increase and continuous fluorescence measurement) and a cooling step to 40 °C. The Δ cycle threshold method was used for the calculation of relative differences in mRNA abundance with a LightCycler 480 (Roche Molecular Biochemicals, Mannheim, Germany). Data were normalized to the expression of GAPDH. The results were expressed as fold-changes. The RT-PCR primers that were used in this study are listed in <ce:cross-ref refid="appsec1" id="crosref0185">supporting information</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.6" view="all">
                     <ce:label>4.6</ce:label>
                     <ce:section-title id="sectitle0255">Cell apoptosis analysis using AV-FITC/PI double-staining assay</ce:section-title>
                     <ce:para id="p0275" view="all">Apoptosis was determined by flow cytometry in accordance with the manufacturer's instructions. An AV-FITC/PI double-staining assay was used to analyze the apoptosis induced by compound <ce:bold>7d</ce:bold>, for which MDA-MB-231 cells were incubated with different concentrations of compound <ce:bold>7d</ce:bold> or 0.1% DMSO for 48 h. Then the cells were harvested, washed and stained with 5 μL Annexin V-FITC and 5 μL propidium iodide at room temperature in the dark for 15 min. Cells were then analyzed by flow cytometry (488 nm excitation and 600 nm emission filters) using BD FACSCalibur flowcytometer (Becton & Dickinson Company, Franklin Lakes, NJ).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.7" view="all">
                     <ce:label>4.7</ce:label>
                     <ce:section-title id="sectitle0260">Cell proliferation assay</ce:section-title>
                     <ce:para id="p0280" view="all">The anti-proliferative activity of the compounds with respect to human breast cancer MDA-MB-231 cells was measured using colony forming assays. Cells were plated in 6-well culture plates (1000 cells per well), and treated by vehicle and <ce:bold>7d</ce:bold> at different concentrations on the following day for 48 h. Then culture medium containing vehicle and <ce:bold>7d</ce:bold> were discarded, and cells were subcultured to fresh medium. Cells were allowed to grow for 10–14 days until the colonies were visible. The cells in plates were then stained with crystal violet solution (Sigma Aldrich, St. Louis, MO) and the colonies were taken photos manually.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.8" view="all">
                     <ce:label>4.8</ce:label>
                     <ce:section-title id="sectitle0265">In vivo xenograft tumor assays</ce:section-title>
                     <ce:para id="p0285" view="all">Adult female Kunming mice (4–6 weeks of age), of Specified-Pathogens Free (SPF) grade, were purchased from the Experimental Animal Center of Yangzhou University (Yangzhou, China). Mice were group-housed in polysulfone cages with bedding material, and were housed in a room with controlled humidity (50 ± 10%) and temperature (25 ± 3 °C) under a 12/12 h light/dark cycle. The animals were given free access to standard diet and water and were allowed to acclimate for 5 days before treatment. Freshly harvested breast cancer cells 4T1 (2.5 × 10<ce:sup loc="post">6</ce:sup> cells per mouse, resuspended in 100 μL PBS) were injected into the armpit of the mice, and then randomly assigned into four groups (6–7 mice per group). The mice were given 10 or 20 mg/kg compound <ce:bold>7d</ce:bold>, or vehicle <ce:italic>p.o.</ce:italic> once daily or 1 mg/kg doxorubicin <ce:italic>i.p.</ce:italic> every four days when the tumor weight reached 1.9 g. Drugs were dissolved in 60% physiological saline with 40% polyethylene glycol for <ce:italic>in vivo</ce:italic> administration. Body weights were measured every other day. On the 14th day, all mice were killed, and the tumor was segregated, weighed, and stored in −80 °C for later use. Tumor inhibitory ratio TI (%) was calculated as TI (%) = (1 − WT/WC) × 100, where WT and WC were the average tumor weights of the treated and control group, respectively.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.9" view="all">
                     <ce:label>4.9</ce:label>
                     <ce:section-title id="sectitle0270">Molecular docking studies</ce:section-title>
                     <ce:para id="p0290" view="all">Docking studies were performed with computational docking program AutoDock4.2. Compound <ce:bold>7d</ce:bold> were docked using the Lamarckian Genetic Algorithm. The Schrodinger software was employed to prepare the macromolecule and ligand. Gasteiger charges were assigned to the ligands by AutoDockTools. AutoGrid maps were further precomputed for all atom types in the ligand set. After completing 10 million energy evaluations, the root-mean-square deviation threshold was set as 2.0 Å and all the resulting conformations of the ligands in the binding pocket of the macromolecule were clustered. The lowest energy clusters were identified and binding energies were evaluated.</ce:para>
                  </ce:section>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0275">Acknowledgments</ce:section-title>
               <ce:para id="p0295" view="all">We gratefully acknowledge the financial support from <ce:grant-sponsor id="gs1" sponsor-id="http://dx.doi.org/10.13039/501100001809" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Natural Science Foundation of China</ce:grant-sponsor> (Grant No. <ce:grant-number refid="gs1">81402791</ce:grant-number> and No. <ce:grant-number refid="gs1">81673298</ce:grant-number>), <ce:grant-sponsor id="gs2" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Natural Science Foundation of the Jiangsu Higher Education Institutions of China</ce:grant-sponsor> (Grant No. <ce:grant-number refid="gs2">BK20140670</ce:grant-number>), <ce:grant-sponsor id="gs3" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Program for Changjiang Scholars and Innovative Research Team in University</ce:grant-sponsor> (IRT_<ce:grant-number refid="gs3">15R63</ce:grant-number>), Project Funded by the <ce:grant-sponsor id="gs4" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)</ce:grant-sponsor>.</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0280">Supplementary data</ce:section-title>
                  <ce:para id="p0300" view="all">The following is the supplementary data related to this article:<ce:display>
                        <ce:e-component id="mmc1">
                           <ce:label>Online data</ce:label>
                           <ce:alt-text role="short" id="alttext0015">Online data</ce:alt-text>
                           <ce:link locator="mmc1" xlink:type="simple" xlink:href="pii:S022352341630890X/mmc1"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0285">Supplementary data</ce:section-title>
                  <ce:para id="p0305" view="all">Supplementary data related to this article can be found at <ce:inter-ref xlink:href="doi:10.1016/j.ejmech.2016.10.028" id="intref0015" xlink:type="simple">http://dx.doi.org/10.1016/j.ejmech.2016.10.028</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0290">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Bowman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Niu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Minton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Muro-Cacho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.E.</ce:given-name>
                                 <ce:surname>Cox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Falcone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Fairclough</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Parsons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Laudano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gazit</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Levitzki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>A</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Constitutive activation of STAT3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2499</sb:first-page>
                              <sb:last-page>2513</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Boengler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hilfiker-Kleiner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Drexler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Heusch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Schulz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The myocardial JAK/STAT pathway: from protection to failure</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>120</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>172</sb:first-page>
                              <sb:last-page>185</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pardoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STATs in cancer inflammation and immunity: a leading role for STAT3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>798</sb:first-page>
                              <sb:last-page>809</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Debnath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Neamati</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecule inhibitors of signal transducer and activator of transcription 3 (STAT3) protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6645</sb:first-page>
                              <sb:last-page>6668</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Crowe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Goldstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>41</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1181</sb:first-page>
                              <sb:last-page>1191</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4402</sb:first-page>
                              <sb:last-page>4412</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Siveen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sikka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Surana</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Dai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.K.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sethi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bishayee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochimica biophysica acta</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1845</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>136</sb:first-page>
                              <sb:last-page>154</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Herrmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Hoon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Forman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Riggs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>109</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7765</sb:first-page>
                              <sb:last-page>7769</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.L.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.J.</ce:given-name>
                                 <ce:surname>Guan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Chatterjee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.E.</ce:given-name>
                                 <ce:surname>Chin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 dimerization regulated by reversible acetylation of a single lysine residue</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>307</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>269</sb:first-page>
                              <sb:last-page>273</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Cherukuri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activation of STAT3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>280</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>11528</sb:first-page>
                              <sb:last-page>11534</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cancer chemopreventive activity of resveratrol, a natural product derived from grapes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>275</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>218</sb:first-page>
                              <sb:last-page>220</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Erion</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dietrich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.I.</ce:given-name>
                                 <ce:surname>Shulman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Horvath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 inhibition of gluconeogenesis is downregulated by SirT1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>492</sb:first-page>
                              <sb:last-page>500</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Carbó</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Costelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.M.</ce:given-name>
                                 <ce:surname>Baccino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.J.</ce:given-name>
                                 <ce:surname>López-Soriano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Argilés</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. biophys. Res. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>254</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>739</sb:first-page>
                              <sb:last-page>743</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Quideau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Deffieux</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Pouysegu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Resveratrol still has something to say about aging</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Angew. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6824</sb:first-page>
                              <sb:last-page>6826</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kotha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sekharam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cilenti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Siddiquee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Khaled</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Zervos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Carter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Resveratrol inhibits Src and STAT3 signaling and induces the apoptosis of malignant cells containing activated STAT3 protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>621</sb:first-page>
                              <sb:last-page>629</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Nardini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Pisu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Gentili</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Natella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Di Felice</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Piccolella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Scaccini</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effect of caffeic acid on tert-butyl hydroperoxide-induced oxidative stress in U937</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Free Radic. Biol. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1098</sb:first-page>
                              <sb:last-page>1105</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Jung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.S.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.H.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.N.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Chung</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Carcinogenesis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1780</sb:first-page>
                              <sb:last-page>1787</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Dai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis, in vitro and in vivo antitumor activity of scopoletin-cinnamic acid hybrids</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>93</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>300</sb:first-page>
                              <sb:last-page>307</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Al-Riyami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Pineda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Rzepecka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Huggan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.I.</ce:given-name>
                                 <ce:surname>Khalaf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Suckling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.J.</ce:given-name>
                                 <ce:surname>Scott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.T.</ce:given-name>
                                 <ce:surname>Rodgers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Harnett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Harnett</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Designing anti-inflammatory drugs from parasitic worms: a synthetic small molecule analogue of the Acanthocheilonema viteae product ES-62 prevents development of collagen-induced arthritis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9982</sb:first-page>
                              <sb:last-page>10002</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Lion</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.S.</ce:given-name>
                                 <ce:surname>Matthews</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.G.</ce:given-name>
                                 <ce:surname>Stevens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Westwell</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis, antitumor evaluation, and apoptosis-inducing activity of hydroxylated (E)-Stilbenes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>48</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1292</sb:first-page>
                              <sb:last-page>1295</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Motoshima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Noguchi-Yachide</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Sugita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hashimoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ishikawa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRalpha-selective antagonists</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5001</sb:first-page>
                              <sb:last-page>5014</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Lan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.F.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.B.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.Y.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and evaluation of novel tacrine-(beta-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6089</sb:first-page>
                              <sb:last-page>6104</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Barontini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bernini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Carastro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Gentili</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Romani</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and DPPH radical scavenging activity of novel compounds obtained from tyrosol and cinnamic acid derivatives</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>New J. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>38</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>809</sb:first-page>
                              <sb:last-page>816</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>D'Ambrosio</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Performances of CN-columns for the analysis of gamma-oryzanol and its p-coumarate and caffeate derivatives by normal phase HPLC and a validated method of quantitation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Food Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>138</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2079</sb:first-page>
                              <sb:last-page>2088</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Abe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Komiyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hattori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Daneshtalab</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis, anti-fungal and 1,3-beta-D-glucan synthase inhibitory activities of caffeic and quinic acid derivatives</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7009</sb:first-page>
                              <sb:last-page>7014</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Marzec</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.N.</ce:given-name>
                                 <ce:surname>Raghunath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nagasawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Wasik</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6948</sb:first-page>
                              <sb:last-page>6953</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Niu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.L.</ce:given-name>
                                 <ce:surname>Wright</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Wright</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Irby</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Briggs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Karras</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.D.</ce:given-name>
                                 <ce:surname>Cress</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pardoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Role of STAT3 in regulating p53 expression and function</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7432</sb:first-page>
                              <sb:last-page>7440</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Uchida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Grammer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Blenis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 serine phosphorylation by ERK-dependent and independent pathways negatively modulates its tyrosine phosphorylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6508</sb:first-page>
                              <sb:last-page>6516</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Takeda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kaisho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Yoshida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Takeda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kishimoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Akira</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific STAT3-deficient mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>161</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4652</sb:first-page>
                              <sb:last-page>4660</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Masuda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Suzui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Yasumatu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nakashima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kuratomi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Azuma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Tomita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Komiyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.B.</ce:given-name>
                                 <ce:surname>Weinstein</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Constitutive activation of signal transducers and activators of transcription 3 correlates with Cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3351</sb:first-page>
                              <sb:last-page>3355</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT1 as a key modulator of cell death</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell. Signal.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>454</sb:first-page>
                              <sb:last-page>465</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.Z.</ce:given-name>
                                 <ce:surname>Xia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.D.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.D.</ce:given-name>
                                 <ce:surname>Geng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.Y.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Schisandrin A enhances the cytotoxicity of doxorubicin by the inhibition of nuclear factor-kappa B signaling in a doxorubicin-resistant human osteosarcoma cell line</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>RSC Adv.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>13972</sb:first-page>
                              <sb:last-page>13984</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Boatright</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Salvesen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mechanisms of caspase activation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>725</sb:first-page>
                              <sb:last-page>731</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Conus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Perozzo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Reinheckel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Peters</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Scapozza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yousefi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.U.</ce:given-name>
                                 <ce:surname>Simon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Caspase-8 is activated by cathepsin D initiating neutrophil apoptosis during the resolution of inflammation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Exp. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>205</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>685</sb:first-page>
                              <sb:last-page>698</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.S.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.D.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates Procaspase-9</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>274</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>11549</sb:first-page>
                              <sb:last-page>11556</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Donepudi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Sweeney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Briand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Grutter</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Insights into the regulatory mechanism for Caspase-8 activation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>543</sb:first-page>
                              <sb:last-page>549</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kominami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Nakabayashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nagai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tsujimura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Chiba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kimura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Miyawaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sawasaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yokota</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Manabe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Sakamaki</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The molecular mechanism of apoptosis upon caspase-8 activation: quantitative experimental validation of a mathematical model</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochimica biophysica acta</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1823</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1825</sb:first-page>
                              <sb:last-page>1840</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Terry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>498</sb:first-page>
                              <sb:last-page>507</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.F.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.T.</ce:given-name>
                                 <ce:surname>Tai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Hsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Shiau</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>220</sb:first-page>
                              <sb:last-page>227</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Zou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tumor Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>13</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.B.</ce:given-name>
                                 <ce:surname>Shaikh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Present advances and future perspectives of molecular targeted therapy for osteosarcoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Mol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>506</sb:first-page>
                              <sb:last-page>527</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Henning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.V.</ce:given-name>
                                 <ce:surname>Vadgama</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>RSC Adv.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>35242</sb:first-page>
                              <sb:last-page>35250</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>